

Boron Appended Ru-NHC Catalyzed Selective Deoxygenative Hydrogenation of Tertiary Amides and Desulfurization of Thioamides

Raju Sharma,^a Gowtham Kenguva,^b Rambabu Dandela^b and Prosenjit Daw^{*a}

^a Department of Chemical Sciences, Indian Institute of Science Education and Research Berhampur, Transit Campus, (Govt. ITI Building), Engg. School Junction, Berhampur 760010, Odisha, India

^b Department of Industrial and Engineering Chemistry, Institute of Chemical Technology, Indian Oil Odisha Campus, Samantpuri, Bhubaneswar 751013, Odisha, India

Corresponding Author

Email: pdaw@iiserbpr.ac.in

Contents:

1. General experimental details	3
2. Synthetic Procedure of Ligand L1-L3.....	5
3. Synthetic Procedure of Metal Complexes 1-3, 1-PF ₆ and 1-BF ₄	9
3.1. Synthetic procedure of Complex 1	9
3.2. Synthetic procedure of complex 1-PF ₆	10
3.3. Synthetic procedure of complex 2.....	11
3.4. Synthetic procedure of complex 3.....	12
3.5. Synthetic procedure of complex 1-BF ₄	13
Table S1. Optimization Table for Tertiary Amide Hydrogenation ^a	14
4. General Procedure for Synthesis of Tertiary Amides	15
5. General Procedure for Synthesis of Amide (4w).....	17
Table S2. Optimization Table for Tertiary Thioamide Hydrogenation ^a	19
6. General Procedure for Synthesis of Tertiary Thioamides	19
7. General Procedure for Synthesis of Primary Thioamides	21
8. Typical Procedure for Catalytic Deoxygenative Reduction of Tertiary Amides	24
9. Characterization of Amine Products Derived from Tertiary Amides	24
10. Typical Procedure for Catalytic Desulfurization of Tertiary Thioamides	29
11. Characterization of Amine Products Derived from Tertiary Thioamides	29
12. Typical Procedure for Catalytic Desulfurizative Hydrogenation of Primary Thioamides	31
13. Characterization of Nitrile Products Derived from Primary Thioamides.....	31
14. Control Experiments	33
14.1. Evaluating the role of appended Lewis basic arm	33
14.2. Evaluating the role of appended Lewis acidic boron arm.....	34
14.2.1. Catalytic reaction of amide 4a using complex 3	34
14.2.2. Catalytic reaction of amide 4a using complex 3 and external Ph(CH ₂) ₂ Bpin.....	35
14.2.3. Catalytic reaction of amide 4a using only Ph(CH ₂) ₂ Bpin	37
14.3. Catalytic hydrogenation of acetophenone using complex 1	38
15. Homogeneity test using mercury drop experiment.....	41
16. Mechanistic Studies	42
16.1. Generation of [Ru-H] species using complex 1.....	42


16.2. Stoichiometric reaction of in-situ generated Ru-H intermediate with amide 4a.....	44
16.3. Catalytic reaction of in-situ generated Ru-H intermediate (A) with amide 4a using a fewer equiv. of PhSiH ₃	46
16.4. Variable Temperature (VT) NMR study for the detection of appended boron-substrate interaction in complex 1	47
16.4.1. Variable Temperature (VT) NMR study of complex 1 and complex 1 +amide 4a	47
16.4.2. Variable Temperature (VT) NMR study using dimethylaminopyridine (DMAP) and complex 1	49
16.5. ESI-HRMS control experiment of stoichiometric reaction of a 1:1:1 mixture of complex 1, PhSiH ₃ and 4a.....	51
16.6. Identification of siloxane by-product	52
17. ¹ H NMR monitoring of 5a formation with progress of time	54
18. Spectroscopic data	55
19. Deoxygenative hydrogenation of secondary amide	137
20. Scale-up reaction of deoxygenative hydrogenation of 4a to 5a using complex 1.....	158
21. Dehydrogenation of benzylamine using complex 1	159
22. GC-TCD analysis of H ₂ gas release during desulfurization of thioamide 8a to nitrile 9a using complex 1	160
23. Synthetic procedure and characterization data for 1,3-Diphenyldisiloxane	161
24. Deoxygenative hydrogenation of 4a to 5a using 1,3-diphenyldisiloxane (DPDS) as the hydride source	163
25. Variable Temperature (VT) NMR study for the interaction of appended boron in complex 1 with N,N-Dimethylacetamide (DMA)	166
26. ¹ H NMR monitoring of N,N-Dimethylethanamine formation with the progress of time	169
27. Catalytic deoxygenative hydrogenation of N,N-dimethylacetamide using complex 1	170
28. Plausible Reaction Mechanism	172
29. X-Ray Crystallographic data	173
30. References.....	175

1. General experimental details

All the experiments were performed under a nitrogen-filled glove box atmosphere or by standard schlenk technique unless otherwise stated. All chemicals were purchased from commercial suppliers and used without further purification unless otherwise stated. All the solvents were pre-dried following the literature

processes. ^1H , ^{13}C , and ^{11}B NMR spectra were recorded on 400 MHz FT-NMR Bruker AVANCE NEO Ascend 400 spectrometer. The chemical shifts (δ) for ^1H NMR are given in parts per million (ppm) referenced to the residual proton signal of the deuterated solvent (CHCl_3 at δ 7.26 ppm, C_6H_6 at 7.16 ppm, DMSO, ^1H ; 2.50 ppm and ^{13}C ; 39.52 ppm). Coupling constants are expressed in hertz (Hz). ^{13}C NMR spectra were referenced to the carbon signal of CDCl_3 (77.16 ppm). The following abbreviations are used to describe NMR signals: s = singlet, d = doublet, t = triplet, m = multiplet, dd = doublet of doublets, q = quartet. High-resolution mass Spectrometry (ESI-HRMS) was performed on Xevo G2-XS QT of Quadrupole Time of Flight Mass spectrometer waters. Elemental analysis was done using the UNICUBE CHNSO element analyzer. The single crystal data was collected on Bruker D8 quest diffractometer. IR spectra were recorded on Bruker TENSOR II FT-IR Spectrometer. The abbreviation br = broad in IR spectral data. The GCMS analysis of the crude reaction mixture was analyzed by GCMS-FID (TRACE 1610, TG-5MS column). Silver Oxide (Ag_2O) was purchased from Sigma-Aldrich and used as directly. $\text{RuCl}_3 \cdot 3\text{H}_2\text{O}$ was purchased from Arora-Matthey. Dichloro(p-Cymene)ruthenium(II) dimer was prepared according to the procedure in the literature.¹ 2-(3-bromopropyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was prepared following the literature procedure.² 4,4,5,5-tetramethyl-2-phenethyl-1,3,2-dioxaborolane i.e $\text{Ph}(\text{CH}_2)_2\text{Bpin}$ was prepared according to literature procedure.³

2. Synthetic Procedure of Ligand L1-L3



Scheme S1: Synthesis of Ligand L1

Synthesis of 2-bromo-6-(piperidine-1-yl)pyridine⁴:

In a 100 mL round bottom flask equipped with a condenser, 2,6-dibromopyridine (2 g, 8.44 mmol) and potassium carbonate (1.75 g, 12.66 mmol) were taken under nitrogen atmosphere. 10 mL of dry 1,4-dioxane was added followed by the addition of 1.6 mL of piperidine (16.88 mmol) and heated the solution at 110° C for 24 h. After completion of the reaction, the solvent was evaporated under a vacuum and the crude product was isolated using silica column chromatography eluted with 20 % ethyl acetate/ hexane mixture to afford the desired product as a colorless oil (1.93 g, 95 %).

¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.31 – 7.28 (m, 1H), 6.71 (d, *J* = 7.4 Hz, 1H), 6.54 (d, *J* = 8.4 Hz, 1H), 3.55 (s, 4H), 1.68 (s, 6H).

¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 159.47, 140.24, 139.33, 115.18, 104.90, 46.14, 25.57, 24.72.

135-DEPT NMR (101 MHz, CDCl₃) δ (ppm) = 139.24, 114.88, 104.64, 45.94, 25.37, 24.52.

ESI-HRMS (*m/z*), [M+H]⁺: Calc. 241.0340; Found 241.0349. (M= C₁₀H₁₃N₂Br)

Synthesis of 2-(1H-imidazol-1-yl)-6-(piperidin-1-yl)pyridine:

In a 50 mL sealed tube, cesium carbonate (2.7 g, 8.28 mmol), imidazole (0.28 g, 4.14 mmol) and copper iodide (0.315 g, 1.65 mmol) were added under nitrogen atmosphere. 8 mL of dry DMF was added followed by the addition of 2-bromo-6-(piperidine-1-yl)pyridine (1 g, 4.14 mmol) in 2 mL DMF, and the tube was sealed and heated at 120 °C for 48 hours. After the completion of the reaction, the solvent was evaporated under reduced pressure and the crude product was purified using silica column chromatography eluted with 80 % ethyl acetate/ hexane mixture to afford the desired product as a pale brown liquid (862.15 mg, 91 %).

¹H NMR (400 MHz, CDCl₃) δ (ppm) = 8.29 (s, 1H), 7.57 (s, 1H), 7.52 (t, *J* = 8.0 Hz, 1H), 7.14 (s, 1H), 6.54 (dd, *J* = 9.3, 8.3 Hz, 2H), 3.59 (s, 4H), 1.66 (s, 6H).

¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 158.71, 147.71, 139.97, 135.14, 130.10, 116.30, 104.62, 99.19, 46.16, 25.55, 24.82.

ESI-HRMS (*m/z*), [M+H]⁺: Calc. 229.1453; Found 229.1448. (M= C₁₃H₁₆N₄)

Synthesis of ligand **L1**:

To a mixture of 2-(1H-imidazol-1-yl)-6-(piperidin-1-yl)pyridine (150 mg, 0.657 mmol) and 2-(3-bromopropyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (180 mg, 0.722 mmol) under a nitrogen atmosphere was added 5 mL of dry acetonitrile and heated the solution at 100 °C for 24 hours. The solution was completely evaporated which afforded an off-white foamy solid that was washed thoroughly with (5 x 5 mL) dry diethyl ether to afford a desired imidazolium salt **L1** as a white solid (272.45 mg, 87%).⁵ The single crystal suitable for X-ray diffraction analysis of **L1** was grown by vapor diffusion of diethyl ether into a concentrated acetonitrile solution of **L1** at room temperature.

¹H NMR (400 MHz, CDCl₃) δ (ppm): 11.28 (s, 1H), 8.11 (s, 1H), 7.64 (t, *J* = 8.0 Hz, 1H), 7.42 (d, *J* = 8.2 Hz, 2H), 6.66 (d, *J* = 8.5 Hz, 1H), 4.54 (t, *J* = 7.0 Hz, 2H), 3.57 (s, 4H), 2.10 – 2.03 (m, 2H), 1.65 (s, 6H), 1.21 (s, 12H), 0.85 (t, *J* = 7.7 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃) δ (ppm): 158.23, 144.42, 141.16, 135.60, 121.91, 118.62, 107.72, 101.10, 83.59, 52.11, 46.09, 25.45, 25.27, 24.95, 24.59.


135-DEPT NMR (101 MHz, CDCl₃) δ (ppm) = 140.94, 135.39, 121.70, 118.41, 107.50, 100.88, 51.89, 45.87, 25.23, 25.06, 24.74, 24.38.

¹¹B NMR (128 MHz, CDCl₃) δ (ppm) = 33.69 (br).

ESI-HRMS (*m/z*), [M-Br]⁺: Calc. 397.2775; Found 397.2788. (M= C₂₂H₃₄BBrN₄O₂)

IR (ATR) $\bar{\nu}$ (cm⁻¹) = 3036, 2926, 2854, 1617, 1556, 1534, 1495, 1444, 1374, 1318, 1282, 1226, 1203, 1141, 1127, 1089, 1027, 999, 971, 935, 855, 831, 785.

Anal. calcd. for C₂₂H₃₄BBrN₄O₂ (%): C, 55.37; H, 7.18; N, 11.74. found: C, 53.39; H, 7.14; N, 11.36.



Scheme S2: Synthesis of ligand **L2**

To a mixture of 2-(1H-imidazol-1-yl)pyridine (205 mg, 1.41 mmol) and 2-(3-bromopropyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (386.8 mg, 1.55 mmol) under a nitrogen atmosphere was added 5 mL of dry acetonitrile and heated the solution at 100 °C for 24 hours. The solution was completely evaporated which afforded an off-white foamy solid that was washed thoroughly with (5 x 5 mL) dry diethyl ether to afford a desired imidazolium salt **L2** as a white solid (499.9 mg, 90%).

¹H NMR (400 MHz, CDCl₃) δ (ppm) = 11.71 (s, 1H), 8.63 (d, *J* = 8.2 Hz, 1H), 8.50 (d, *J* = 4.5 Hz, 1H), 8.32 (s, 1H), 8.05 (t, *J* = 7.8 Hz, 1H), 7.43 (s, 2H), 4.54 (t, *J* = 7.2 Hz, 2H), 2.15 – 2.07 (m, 2H), 1.22 (s, 12H), 0.88 (t, *J* = 7.8 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 148.99, 146.11, 140.89, 136.14, 125.26, 122.17, 118.89, 115.41, 83.69, 52.32, 25.22, 24.99.


135-DEPT NMR (101 MHz, CDCl₃) δ (ppm) = 148.79, 140.69, 135.89, 125.07, 122.01, 118.73, 115.19, 52.15, 25.01, 24.78.

¹¹B NMR (128 MHz, CDCl₃) δ (ppm) = 33.35 (br).

ESI-HRMS (*m/z*), [M-Br]⁺: Calc. 314.2040; Found 314.2045 (M= C₁₇H₂₅BBrN₃O₂)

IR (ATR) $\bar{\nu}$ (cm⁻¹) = 2973, 1600, 1544, 1476, 1441, 1406, 1362, 1330, 1297, 1273, 1220, 1144, 1113, 1077, 995, 967, 884, 846, 775, 733.

Anal. calcd. for C₁₇H₂₅BBrN₃O₂ (%): C, 51.81; H, 6.39; N, 10.66 found: C, 49.22; H, 6.18; N, 10.90.



Scheme S3: Synthesis of ligand **L3**

Synthesis of ligand **L3**:

In a 25 mL shlenck tube, 2-(1H-imidazol-1-yl)-6-(piperidin-1-yl)pyridine (150 mg, 0.657 mmol) and 5 mL of dry acetonitrile was added under a nitrogen atmosphere followed by the addition of 78 μ L of butyl bromide (99 mg, 0.722 mmol) and heated the solution at 100 $^{\circ}$ C for 24 hours. The solution was completely evaporated which afforded an off-white solid that was washed thoroughly with (5 x 5 mL) dry diethyl ether to afford a desired imidazolium salt **L3** as a white solid (216.68 mg, 90%).

^1H NMR (400 MHz, CDCl_3) δ (ppm) = 11.47 (s, 1H), 8.08 (s, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.44 (d, J = 6.9 Hz, 1H), 7.37 (s, 1H), 6.69 (d, J = 8.5 Hz, 1H), 4.59 (s, 2H), 3.59 (s, 4H), 1.98 (br s, 2H), 1.65 (s, 6H), 1.45 (dd, J = 13.5, 6.8 Hz, 2H), 0.99 (t, J = 7.1 Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ (ppm) = 158.29, 144.39, 141.32, 136.15, 121.63, 118.76, 107.85, 101.32, 50.58, 46.19, 32.59, 25.52, 24.63, 19.77, 13.75.

135-DEPT NMR (101 MHz, CDCl_3) δ (ppm) = 140.92, 135.03, 122.09, 118.63, 108.00, 101.31, 50.08, 46.31, 32.15, 25.06, 24.12, 19.31, 13.35.


ESI-HRMS (m/z), $[\text{M}-\text{Br}]^+$: Calc. 285.2079; Found 285.2108 ($\text{M} = \text{C}_{17}\text{H}_{25}\text{BrN}_4$)

IR (ATR) $\bar{\nu}$ (cm^{-1}) = 3052, 2934, 2859, 1617, 1555, 1531, 1504, 1445, 1358, 1251, 1199, 1178, 1121, 1091, 1022, 974, 932, 875, 857, 787, 772, 746.

Anal. calcd. for $\text{C}_{17}\text{H}_{25}\text{BrN}_4$ (%): C, 55.89; H, 6.90; N, 15.34 found: C, 55.39; H, 7.08; N, 14.62.

3. Synthetic Procedure of Metal Complexes 1-3, 1-PF₆ and 1-BF₄

3.1. Synthetic procedure of Complex 1



Scheme S4: Synthesis of metal complex 1

In a 25 mL oven dried shlenck tube, imidazolium salt **L1** (110 mg, 0.23 mmol), silver oxide (26.7 mg, 0.115 mmol) were added under a nitrogen atmosphere followed by the addition of 10 mL of dry acetonitrile. The solution was stirred at room temperature under dark for 16 hours after which [Ru(p-Cymene)Cl₂]₂ (70.4 mg, 0.115 mmol) was added directly under a nitrogen atmosphere and stirred the solution for an additional 24 hours. The solution was completely evaporated under a vacuum and 20 mL of dry THF was added and filtered the solution through celite. The filtrate was concentrated to 1 mL and 10 mL of dry diethyl ether was added which precipitated a light-yellow solid that was further washed with (5x 5 mL) diethyl ether to obtain the desired complex **1** as a light yellow solid (145.65 mg, 90%).

¹H NMR (400 MHz, CDCl₃) δ (ppm) = 8.50 (s, 1H), 8.03 (s, 2H), 7.38 (s, 1H), 7.06 (s, 1H), 6.17 (d, *J* = 5.0 Hz, 1H), 5.92 (s, 1H), 5.82 (d, *J* = 4.8 Hz, 1H), 5.32 (s, 1H), 4.42 (s, 1H), 4.24 (s, 1H), 3.33 (s, 2H), 2.21 (s, 5H), 2.09 (s, 1H), 1.91 (s, 2H), 1.76 (s, 6H), 1.28 (s, 12H), 0.97 (t, *J* = 6.8 Hz, 2H), 0.83 (dd, *J* = 14.9, 6.4 Hz, 6H).

¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 182.05, 169.12, 152.42, 143.33, 124.71, 113.15, 109.23, 94.39, 85.88, 83.67, 53.34, 31.21, 25.49, 25.44, 25.18, 25.06, 24.01, 22.84, 22.51, 19.10.

DEPT-135 NMR (101 MHz, CDCl₃) δ (ppm) = 142.66, 124.07, 112.98, 108.81, 94.13, 85.17, 52.93, 30.96, 25.20, 25.15, 24.91, 24.79, 23.75, 22.40, 22.01, 18.71.


¹¹B NMR (128 MHz, CDCl₃) δ (ppm) = 33.26 (br).

ESI- HRMS (*m/z*), [**1**-Cl]⁺: Calc. 667.2524; Found 667.2524 (**1**= C₃₂H₄₇BCl₂N₄O₂Ru)

IR (ATR) $\bar{\nu}$ (cm⁻¹) = 3085, 2965, 2931, 1613, 1561, 1476, 1374, 1323, 1247, 1211, 1142, 1106, 1055, 1031, 967, 922, 845, 800, 740, 694, 674.

Anal. calcd. for $C_{32}H_{47}BCl_2N_4O_2Ru \cdot CH_2Cl_2$ (%): C, 50.33; H, 6.27; N, 7.12 found: C, 50.02; H, 6.19; N, 7.33.

3.2. Synthetic procedure of complex 1-PF₆



Scheme S5: Synthesis of metal complex 1-PF₆

In a 25 mL oven-dried shlenck tube, complex 1 (100 mg, 0.142 mmol) and KPF₆ (39.3 mg, 0.213 mmol) were added under a nitrogen atmosphere, followed by the addition of 10 mL of dry dichloromethane. The solution was heated at 50 °C for 24 hours in an oil bath. During this time, the light yellowish solution turns to light brown. The solution was completely evaporated under the vacuum and 20 mL of dry THF was added to dissolve the residue and filtered the solution through celite. The filtrate was concentrated to 1 mL and 10 mL of dry diethyl ether was added which precipitated a brown solid that was further washed with (5x 5 mL) diethyl ether to obtain the desired complex **1-PF₆** as a light brown solid (99.45 mg, 86%). The single crystal suitable for X-ray diffraction analysis of **1-PF₆** was grown by vapor diffusion of diethyl ether into a concentrated THF solution of complex at 5 °C.

¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.87 (t, *J* = 8.0 Hz, 1H), 7.65 (br s, 1H), 7.31 (br s, 1H), 7.23 (br s, 1H), 7.01 (d, *J* = 8.2 Hz, 1H), 6.09 (d, *J* = 6.1 Hz, 1H), 5.84 (d, *J* = 5.9 Hz, 1H), 5.77 (d, *J* = 6.1 Hz, 1H), 5.31 (d, *J* = 5.7 Hz, 1H), 4.41 – 4.34 (m, 1H), 4.28 – 4.21 (m, 1H), 3.41 (t, *J* = 8 Hz, 2H), 2.17 (s, 3H), 2.15 – 2.04 (m, 3H), 1.90 (br s, 2H), 1.74 (br s, 4H), 1.59 (br s, 2H), 1.28 (s, 12H), 0.95 (t, *J* = 7.6 Hz, 2H), 0.84 (d, *J* = 6.9 Hz, 3H), 0.78 (d, *J* = 6.9 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 182.99, 169.38, 152.22, 142.12, 124.19, 117.39, 112.92, 105.80, 94.24, 85.13, 83.71, 52.81, 31.03, 25.39, 25.25, 25.12, 25.02, 24.03, 22.50, 21.82, 18.72.

DEPT 135-NMR (176 MHz, CDCl₃) δ (ppm) = 141.92, 123.99, 117.18, 112.71, 105.60, 52.60, 30.83, 25.04, 24.92, 24.81, 23.82, 22.30, 21.61, 18.51.

¹¹B NMR (128 MHz, CDCl₃) δ (ppm) = 33.98 (br).


^{31}P NMR (162 MHz, CDCl_3) δ (ppm) = -144.31 (m).

^{19}F NMR (377 MHz, CDCl_3) δ (ppm) = -72.79 (d).

ESI-HRMS (m/z), $[\text{M-PF}_6]^+$: Calc. 667.2524; Found 667.2524. ($\text{M} = \text{C}_{32}\text{H}_{47}\text{BClF}_6\text{N}_4\text{O}_2\text{PRu}$)

Anal. calcd. for $\text{C}_{32}\text{H}_{47}\text{BClF}_6\text{N}_4\text{O}_2\text{PRu}$ (%): C, 47.33; H, 5.83; N, 6.90 found: C, 46.48; H, 6.00; N, 6.78.

3.3. Synthetic procedure of complex 2



Scheme 6: Synthesis of metal complex 2

In a 25 mL oven dried shlenck tube, imidazolium salt **L2** (100 mg, 0.253 mmol), silver oxide (29.3 mg, 0.126 mmol) were added under a nitrogen atmosphere followed by the addition of 10 mL of dry acetonitrile. The solution was stirred at RT under dark for 16 hours after which $[\text{Ru}(\text{p-Cymene})\text{Cl}_2]_2$ (77.7 mg, 0.126 mmol) was added directly under a nitrogen atmosphere and stirred the solution for an additional 24 hours. The solution was completely evaporated under a vacuum and 20 mL of dry THF was added and filtered the solution using celite. The filtrate was concentrated to 1 mL and 10 mL of dry diethyl ether was added which precipitated a light yellow solid that was further washed with (5x 5 mL) diethyl ether to obtain the desired complex **2** as a light yellow solid (138.3 mg, 93%).

^1H NMR (400 MHz, DMSO) δ (ppm) = 9.34 (d, $J = 5.5$ Hz, 1H), 8.45 (s, 1H), 8.25 (t, $J = 7.7$ Hz, 1H), 8.16 (d, $J = 8.2$ Hz, 1H), 7.86 (s, 1H), 7.52 (t, $J = 6.5$ Hz, 1H), 6.34 (d, $J = 6.1$ Hz, 2H), 6.19 (d, $J = 6.2$ Hz, 1H), 5.71 (d, $J = 5.8$ Hz, 1H), 4.43 – 4.30 (m, 2H), 2.38-2.31 (m, 1H), 2.12 (s, 3H), 1.99 – 1.91 (m, 2H), 1.21 (s, 12H), 1.09 (t, $J = 7.0$ Hz, 2H), 0.83 (dd, $J = 12.6, 6.8$ Hz, 6H).

^{13}C NMR (101 MHz, DMSO) δ (ppm) = 182.98, 155.77, 151.28, 141.54, 125.04, 122.92, 116.91, 112.25, 90.94, 86.27, 82.92, 52.60, 30.39, 24.68, 24.62, 22.19, 21.74, 18.59.

$^{135}\text{-DEPT}$ NMR (101 MHz, DMSO) δ (ppm) = 155.55, 141.35, 124.84, 122.72, 116.68, 112.02, 90.74, 86.04, 52.39, 30.19, 24.46, 24.42, 21.97, 21.52, 18.38.


^{11}B NMR (128 MHz, DMSO) δ (ppm) = 31.98 (br).

HRMS (m/z), [2-Cl]⁺: Calc. 584.1789; Found 584.1794. (2= C₂₇H₃₈BCl₂N₃O₂Ru)

IR (ATR) $\bar{\nu}$ (cm⁻¹) = 3085, 2964, 1615, 1578, 1493, 1458, 1373, 1326, 1260, 1218, 1140, 1191, 1025, 967, 867, 800, 743, 680.

Anal. calcd. for C₂₇H₃₈BCl₂N₃O₂Ru.2CH₂Cl₂. Et₂O (%): C, 45.91; H, 6.07; N, 4.87 found: C, 46.39; H, 6.18; N, 4.88.

3.4. Synthetic procedure of complex 3



Scheme 7: Synthesis of metal complex 3

In a 25 mL oven dried shlenck tube, imidazolium salt **L3** (130 mg, 0.355 mmol), silver oxide (41.3 mg, 0.178 mmol) were added under a nitrogen atmosphere followed by the addition of 10 mL of dry acetonitrile. The solution was stirred at RT under dark for 16 hours after which [Ru(p-Cymene)Cl₂]₂ (109 mg, 0.178 mmol) was added directly under a nitrogen atmosphere and stirred the solution for an additional 24 hours. The solution was completely evaporated under a vacuum and 20 mL of dry THF was added and filtered the solution through celite. The filtrate was concentrated to 1 mL, and 10 mL of dry diethyl ether was added, which resulted in the precipitation of a light yellow solid that was further washed with (5x 5 mL) diethyl ether to obtain the desired complex **3** as a light yellow solid (194.3 mg, 92.5%).

¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.90 (s, 2H), 7.45 (d, *J* = 4.1 Hz, 1H), 7.32 (s, 1H), 7.01 (d, *J* = 7.4 Hz, 1H), 6.11 (d, *J* = 4.6 Hz, 1H), 5.88 (d, *J* = 4.2 Hz, 1H), 5.77 (d, *J* = 5.3 Hz, 1H), 5.30 (d, *J* = 4.1 Hz, 1H), 4.47 – 4.27 (m, 2H), 3.37 (s, 2H), 2.15 (s, 3H), 1.97 (t, *J* = 8 Hz, 2H), 1.89 (br s, 1H), 1.74 (s, 6H), 1.51 – 1.44 (m, 2H), 1.27 (br s, 2H), 1.01 (t, *J* = 8.0 Hz, 3H), 0.85 (d, *J* = 6.4 Hz, 3H), 0.78 (d, *J* = 6.1 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 181.89, 168.37, 151.32, 141.24, 123.10, 116.79, 111.85, 105.19, 93.13, 84.12, 82.70, 64.98, 51.81, 50.14, 31.44, 30.03, 24.39, 24.12, 24.01, 22.98, 21.55, 20.70, 19.13, 17.68, 12.91.


$^{135}\text{-DEPT NMR}$ (101 MHz, CDCl_3) δ (ppm) = 141.00, 122.90, 116.46, 111.65, 104.83, 92.93, 83.89, 51.60, 49.92, 31.23, 29.82, 24.18, 23.91, 23.80, 22.78, 21.34, 20.47, 18.92, 17.47, 12.70.

ESI-HRMS (m/z), $[\mathbf{3}\text{-Cl}]^+$: Calc. 555.1829; Found 555.1846. ($\mathbf{3} = \text{C}_{27}\text{H}_{38}\text{Cl}_2\text{N}_4\text{Ru}$)

IR (ATR) $\bar{\nu}$ (cm^{-1}) = 3083, 2964, 1615, 1578, 1493, 1374, 1326, 1260, 1218, 1140, 1091, 1024, 967, 849, 799, 743, 680.

Anal. calcd. for $\text{C}_{27}\text{H}_{38}\text{Cl}_2\text{N}_4\text{Ru}$. CH_2Cl_2 (%): C, 49.78; H, 5.97; N, 8.29 found: C, 47.80; H, 6.32; N, 7.61.

3.5. Synthetic procedure of complex $\mathbf{1}\text{-BF}_4$



Scheme S8: Synthesis of metal complex $\mathbf{1}\text{-BF}_4$

In a 25 mL oven-dried shlenck tube, complex **1** (60 mg, 0.085 mmol) and AgBF_4 (24.93 mg, 0.128 mmol) were added under a nitrogen atmosphere, followed by the addition of 10 mL of dry acetonitrile. The solution was stirred for 16 hours at RT. During this time, the light yellowish solution turns to a yellowish-orange solution. The solution was completely evaporated under the vacuum and 20 mL of dry THF was added to dissolve the residue and filtered the solution through celite. The filtrate was completely evaporated and washed the obtained solid with (5x 5 mL) of dry diethylether to afford the desired complex **1-BF₄** as a light yellowish-orange solid (56.72 mg, 88%).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ (ppm) = 7.90 (t, J = 8.0 Hz, 1H), 7.81 (d, J = 1.8 Hz, 1H), 7.39 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 1.8 Hz, 1H), 7.02 (d, J = 8.2 Hz, 1H), 6.11 (d, J = 6.1 Hz, 1H), 5.86 (d, J = 5.9 Hz, 1H), 5.78 (d, J = 6.1 Hz, 1H), 5.32 (d, J = 5.7 Hz, 1H), 4.42 – 4.35 (m, 1H), 4.28 – 4.21 (m, 1H), 3.39 (s, 2H), 2.18 (s, 3H), 2.15–2.04 (m, 3H), 1.90 (s, 2H), 1.75 (s, 4H), 1.63 (s, 2H), 1.28 (s, 12H), 0.95 (t, J = 7.6 Hz, 2H), 0.85 (d, J = 6.9 Hz, 3H), 0.79 (d, J = 6.9 Hz, 3H).


$^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ (ppm) = 182.71, 169.31, 152.30, 142.31, 124.15, 117.82, 112.93, 106.28, 94.15, 85.20, 83.69, 52.79, 31.03, 25.27, 25.13, 25.02, 24.02, 22.58, 21.88, 18.75.

$^{11}\text{B NMR}$ (128 MHz, CDCl_3) δ (ppm) = 33.28 (br, s), -0.89 (s).

^{19}F NMR (377 MHz, CDCl_3) δ (ppm) = -152.66 (s), -152.71 (s).

ESI-HRMS (m/z), $[\text{M-BF}_4]^{+}$: Calc. 667.2524; Found 667.2499. (M= $\text{C}_{32}\text{H}_{47}\text{B}_2\text{ClF}_4\text{N}_4\text{O}_2\text{Ru}$)

Table S1. Optimization Table for Tertiary Amide Hydrogenation^a




Sl. No.	[Ru] (mol %)	Silane (equiv.)	T ($^\circ\text{C}$)	Time (h)	Solvent (mL)	Yield 5a (%) ^b
1	1 (5)	1	60	24	Toluene	95
2	1 (2)	1	60	24	Toluene	94
3	1 (1)	1	60	24	Toluene	45
4	1 (1)	1	60	48	Toluene	65
5	1 (1)	1	80	24	Toluene	84
6	1 (1)	1	100	24	Toluene	85
7	1 (0.2)	1	100	48	Toluene	22
8	1 (1)	1	80	36	Toluene	85
9	1 (1)	1.1	80	36	Toluene	97
10	1 (1)	1.1	80	24	Toluene	88
11	1 (1)	1.1	60	36	Toluene	75
12	1 (1)	Ph_2SiH_2 (1.1)	80	36	Toluene	55
13	1 (1)	Et_3SiH (1.1)	80	36	Toluene	NR
14	1 (1)	1.1	80	36	Benzene	97
15	1 (1)	1.1	80	36	THF	61
16	1 (1)	1.1	80	36	1,4-dioxane	33
17	1 (1)	1.1	80	36	DCM	30
18	-	1.1	80	36	Toluene	NR
19	$[\text{Ru}(\text{p-Cymene})\text{Cl}_2]_2$ (1)	1.1	80	36	Toluene	20

20 ^c	1 (1)	1.1	80	36	Toluene	90
21	2 (1)	1.1	80	36	Toluene	90
22	3(1)	1.1	80	36	Toluene	38
23	1-PF ₆ (1)	1.1	80	36	Toluene	94
24	1-BF ₄ (1)	1.1	80	36	Toluene	96

^aReaction conditions: **4a** (0.503 mmol, 1 equiv.), **[Ru]** (x mol %), **Silanes** (y equiv. w.r.t **4a**), Toluene (1 mL). ^bYield was determined using ¹H NMR using mesitylene as internal standard. ^cIn the presence of Hg (300 equiv. w.r.t. catalyst **1**). NR= No Reaction,

4. General Procedure for Synthesis of Tertiary Amides

Method A: Tertiary amides were prepared by using a slightly modified literature procedure.⁶




In a 100 mL oven dried round bottom flask, 10 mL of dry DCM was added followed by the addition of amine (3 equiv.) and Et₃N (3 equiv.) and cooled the solution to 0 °C. Acyl chloride (1 equiv.) was added drop wise and allow the solution to warm to room temperature and stir for additional 4 hours. After completion of reaction, excess amine was evaporated under reduced pressure and the solution was extracted with DCM (3 x 20 mL). The organic layer was dried over anhydrous Na₂SO₄, and the filtrate was concentrated under reduced pressure.

For amides **4a-4e**, **4h**, **4o**, and **4p**: Pure product was obtained after removing the solvents.

For amides **4f** and **4g**: Purified with silica gel column chromatography using ethyl acetate/ hexane mixture as the eluent.

Method B: Tertiary amides were prepared by using a slightly modified literature procedure.⁷



In a 100 mL round bottom flask, sodium hydride (2 equiv.) in 15 mL of dry THF was added under nitrogen atmosphere and cooled the solution to 0° C. Secondary amide (1 equiv.) was added in one portion and stirred the solution until H₂ gas evolution ceased. Alkyl or allyl halides (2 equiv.) was added dropwise and the solution was allowed to warm to room temperature and stirred for 4 hours. The solution was evaporated under vacuum and quenched with 20 mL water and extracted with DCM (3 x 20 mL). The organic layer was dried over anhydrous Na₂SO₄, and the filtrate was concentrated to obtain the desired amide in excellent yield.

For amides **4l**, **4n**: Purified with silica gel column chromatography using ethyl acetate/ hexane mixture as the eluent.

Amide **4u** was prepared according to the known literature procedure.⁸

Amide **4w-4z** was prepared following the similar literature procedure⁹ and slightly modified procedure for steps 2-3^{6,7}




Figure S1A. List of tertiary amide substrates (**4a-4z'**)





Figure S1B. List of tertiary amines derived from tertiary amides (**5a'-5z'**)

5. General Procedure for Synthesis of Amide (**4w**)

Amide **4w** was prepared following the known literature procedure⁹ for step 1 and slightly modified procedure for steps 2-3^{6,7}



Step1:

In a 100 mL oven dried two neck round bottom flask, 1-naphthoic acid (1 equiv., 4.64 mmol) was taken under N_2 atmosphere. 10 mL dry DCM was added and the solution was cooled to 0°C . Oxalyl chloride (2 equiv., 9.29 mmol) and four drops of DMF were added dropwise, and the solution was allowed to warm to room temperature and stirred for an additional 5 hours. After completion of the reaction, excess oxalyl chloride and the solvent were evaporated under reduced pressure. The oily liquid obtained was used in the next step without further purification.


Step2:

In a 100 mL oven dried two neck round bottom flask, (4-(tert-butyl)phenyl)methanamine (1.5 equiv., 4.72 mmol) was taken under N_2 atmosphere. 8 mL dry DCM was added and the solution was cooled to 0°C . Triethyl amine (2 equiv., 6.29 mmol) was added dropwise and stirred the solution for 30 minutes, followed by the addition of 1-naphthoyl chloride (1 equiv., 3.14 mmol) in 2 mL of dry DCM and allowing the solution to warm to room temperature and stir for additional 3.5 hours. After completion of reaction, solvent was evaporated under reduced pressure. The residue obtained was purified using silica gel column chromatography (40% EA/hexane mixture) to obtain the desired product N-(4-(tert-butyl)benzyl)-1-naphthamide as a white solid.

Step 3:

In a 100 mL oven dried two neck round bottom flask N-(4-(tert-butyl)benzyl)-1-naphthamide (1 equiv., 1.89 mmol) and NaH (2 equiv., 3.78 mmol) was taken under N_2 atmosphere. 10 mL dry THF was added, and the solution was cooled to 0°C and stirred for 30 minutes until the H_2 gas stopped. Methyl iodide (2 equiv., 3.78 mmol) was added dropwise and stirred the solution for 3.5 hours. After completion of reaction, solvent was evaporated under reduced pressure. The residue obtained was purified using silica gel column chromatography (30% EA/hexane mixture) to obtain the desired product N-methyl-N-(4-(tert-butyl)benzyl)-1-naphthamide as a white solid (92%).

Table S2. Optimization Table for Tertiary Thioamide Hydrogenation^a




Sl. No.	[Ru] (mol %)	Silane (equiv.)	T (° C)	Time (h)	Solvent (mL)	Yield 5a (%) ^b
1	1 (1)	PhSiH ₃ (1.1)	100	24	Toluene	99
2	1 (2)	PhSiH ₃ (1.1)	80	24	Toluene	99
3	1 (1)	PhSiH ₃ (1.1)	60	24	Toluene	98
4	1 (1)	PhSiH ₃ (1.1)	RT	24	Toluene	ND
5	1 (1)	PhSiH₃ (1.1)	60	12	Toluene	98
6	1 (1)	PhSiH ₃ (1.1)	60	6	Toluene	55
7	1 (1)	PhSiH ₃ (1)	60	12	Toluene	90
8	1 (0.5)	PhSiH ₃ (1.1)	60	12	Toluene	54
9	1 (1)	Et ₃ SiH (1.1)	60	12	Toluene	ND
10	1 (1)	PhSiH ₃ (1.1)	60	12	Benzene	98
11	1 (1)	PhSiH ₃ (1.1)	60	12	1,4-Dioxane	47
12	1 (1)	PhSiH ₃ (1.1)	60	12	THF	18
13	3 (1)	PhSiH ₃ (1.1)	60	12	Toluene	35
14	2 (1)	PhSiH ₃ (1.1)	60	12	Toluene	91

^aReaction conditions: **6a** (0.503 mmol, 1 equiv.), **[Ru]** (x mol %), **Silanes** (y equiv. w.r.t 6a), Toluene (1 mL). ^bYield was determined using ¹H NMR using mesitylene as internal standard.

6. General Procedure for Synthesis of Tertiary Thioamides

Tertiary thioamides (**6a-6g** and **6n**) were prepared by using a known literature procedure.¹⁰




Method A:

R= Alkyl or aryl

In a 100 mL oven dried round bottom flask, elemental sulfur (2 equiv.) was taken. 3 mL of THF was added followed by the addition of dimethylamine (40% in H₂O, 5 equiv.) and aldehyde (1 equiv.). The solution was stirred for 16 hours at RT. The solvent and excess amines were removed under reduced pressure. The obtained crude residue was purified using silica gel column chromatography using mixture of ethyl acetate/ Hexane as the eluent.

Tertiary thioamides (**6h-6m**) were prepared by using a slightly modified literature procedure.¹⁰

Method B:



In a 100 mL oven dried round bottom flask, elemental sulfur (2 equiv.) was taken in 3 mL of THF and 1 mL of H₂O was added followed by the addition of pyrrolidine or piperidine (5 equiv.) and aldehyde (1 equiv.). The solution was stirred for 16 hours at RT. The solvent and excess amines were removed under reduced pressure. The obtained crude residue was purified using silica gel column chromatography using mixture of ethyl acetate/ Hexane as the eluent.




Figure S2A. List of tertiary thioamide substrates (**6a-6n**)





Figure S2B. List of tertiary amines derived from tertiary thioamides (**5a-7n**)


7. General Procedure for Synthesis of Primary Thioamides

Primary thioamides (**8a-8f**) were prepared by using a known literature procedure.¹¹



In a 100 mL oven-dried round bottom flask, primary amide (1 equiv.) was taken. 40 mL of diethyl ether was added and cooled the solution to 0 °C. P₂S₅ (0.5 equiv.) was added portion-wise, and the solution was allowed to warm to RT and stir for 16 hours. The solution was filtered through celite and washed thoroughly with diethyl ether and the filtrate obtained was evaporated under vacuum. The crude residue was purified using silica gel column chromatography using ethyl acetate/ Hexane as the eluent.

Table S3. Optimization Table for Primary Thioamide Hydrogenation^a



Sl. No.	[Ru] (mol %)	Silane (equiv.)	T (° C)	Time (h)	Solvent (mL)	Yield 9a (%) ^b
1	1 (1)	PhSiH ₃ (1)	100	12	Toluene	83
2	1 (1)	PhSiH ₃ (1)	100	16	Toluene	94
3	1 (1)	PhSiH ₃ (0.8)	100	16	Toluene	80
4	1 (1)	PhSiH ₃ (1)	90	16	Toluene	63
5	1 (0.5)	PhSiH ₃ (1)	100	16	Toluene	61
6	1 (1)	Ph ₂ SiH ₂ (1)	100	16	Toluene	76
7	1 (1)	PhSiH ₃ (1)	100	16	THF	51
8	1 (1)	PhSiH ₃ (1)	100	16	1,4-Dioxane	62
9	1 (1)	PhSiH ₃ (1)	100	16	DCM	37
10	3 (1)	PhSiH ₃ (1)	100	16	Toluene	67

^aReaction conditions: **8a** (0.503 mmol, 1 equiv.), [**Ru**] (x mol %), **Silanes** (y equiv. w.r.t **8a**), Toluene (1.5 mL). ^bYield was determined using ¹H NMR using mesitylene as internal standard.




Figure S3A. List of primary thioamide substrates (8a-8f)






Figure S3B. List of nitriles derived from primary thioamides (9a-9f)

8. Typical Procedure for Catalytic Deoxygenative Reduction of Tertiary Amides




Inside a N₂ filled glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **1** (3.53 mg, 1 mol%), **4a** (75 mg, 0.503 mmol). 1 mL of dry toluene was added followed by the addition of phenylsilane (59.9 mg, 0.553 mmol) and the closed vessel was heated at 80 °C for 36 hours. After completion of reaction, the solution was cooled down to room temperature and mesitylene (0.503 mmol) was added as internal standard and NMR yield was analyzed using ¹H NMR in CDCl₃ as the solvent. In all cases, the product peaks were integrated with respect to the -CH- peak of the internal standard mesitylene which was normalized to 3. The solution was passed through a small pad of celite and concentrated under reduced pressure. The residue was purified by column chromatography using silica/neutral alumina in EtOAc/ hexane mixture as the eluent. In the case of volatile amine compounds, the product was isolated as a hydrochloride salt using 2 M HCl in diethylether solution.


9. Characterization of Amine Products Derived from Tertiary Amides




N,N-dimethyl-1-phenylmethanamine hydrochloride (5a'): white solid, 68.47 mg (95%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 12.84 (s, 1H), 7.60 (s, 2H), 7.46 (s, 3H), 4.16 (d, *J* = 2.6 Hz, 2H), 2.75 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 131.23, 130.44, 129.61, 128.49, 61.49, 42.44. ESI-HRMS (*m/z*) [M-Cl]⁺, calcd. 136.1126; found 136.1123. (M= C₉H₁₄N)




N,N-dimethyl-1-(m-tolyl)methanamine¹² (5b): Colorless liquid, 67.58 mg (90%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.21 (t, *J* = 7.5 Hz, 1H), 7.14 (s, 1H), 7.08 (t, *J* = 6.6 Hz, 2H), 3.38 (s, 2H), 2.34 (s, 3H), 2.24 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 129.97, 128.23, 127.93, 126.33, 64.57, 45.56, 21.35.




1-(4-methoxyphenyl)-N,N-dimethylmethanamine¹² (5c): Colorless liquid, 73.91 mg (89%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.21 (d, *J* = 8.6 Hz, 2H), 6.85 (d, *J* = 8.6 Hz, 2H), 3.80 (s, 3H), 3.36 (s, 2H), 2.22 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 158.85, 131.09, 130.42, 113.74, 63.86, 55.39, 45.34.




1-benzylmorpholine¹³ (5d): Colorless liquid, 76.35 mg (85%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.31 – 7.23 (m, 5H), 3.69 (t, *J* = 4.8 Hz, 4H), 3.48 (s, 2H), 2.43 (t, *J* = 4.0 Hz, 4H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 137.91, 129.35, 128.40, 127.29, 67.17, 63.62, 53.77. ESI-HRMS (*m/z*) [*M*+*H*]⁺, calcd. 178.1232; found 178.1077. (*M* = C₁₁H₁₅NO)




1-(4-methoxybenzyl)morpholine¹⁴ (5e): Colorless liquid, 80.5 mg (86%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.23 (d, *J* = 8.5 Hz, 2H), 6.85 (d, *J* = 8.6 Hz, 2H), 3.80 (s, 3H), 3.70 (t, *J* = 4.0 Hz, 4H), 3.43 (s, 2H), 2.42 (t, *J* = 4.0 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 158.94, 130.53, 129.88, 113.76, 67.17, 62.99, 55.40, 53.68.




1-(4-fluorobenzyl)morpholine¹⁵ (5f): Yellow liquid, 117.59 mg (84%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.21 (dd, *J* = 8.4, 5.7 Hz, 2H), 6.92 (t, *J* = 8 Hz, 2H), 3.63 (t, *J* = 4 Hz, 4H), 3.38 (s, 2H), 2.35 (t, *J* = 4 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 163.40, 160.96, 133.59, 130.79, 115.29, 115.08, 67.12, 62.75, 53.66. ¹⁹F NMR (377 MHz, CDCl₃) δ (ppm) = -115.76 (s). ESI-HRMS (*m/z*) [*M*+*H*]⁺, calcd. 196.1138; found 196.1001. (*M* = C₁₁H₁₄FNO)




1-(4-(trifluoromethyl)benzyl)morpholine¹⁶ (5g): Yellow liquid, 94.95 mg (77%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.57 (d, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 8.0 Hz, 2H), 3.71 (t, *J* = 4 Hz, 4H), 3.54 (s, 2H), 2.44 (t, *J* = 4 Hz, 4H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 142.33, 129.37, 125.36 (q), 67.12, 62.98, 53.77. ESI-HRMS (*m/z*) [*M*+*H*]⁺, calcd. 246.1106; found 246.0919. (*M* = C₁₂H₁₄F₃NO)




1-(2-methylbenzyl)morpholine (5h): Colorless liquid, 79.98 mg (83%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.25 (d, *J* = 6.4 Hz, 1H), 7.19-7.11 (m, 3H), 3.68 (t, *J* = 4.0 Hz, 4H), 3.46 (s, 2H), 2.44 (s, 4H), 2.37 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 137.75, 130.43, 130.06, 127.30, 125.59, 67.25, 61.42, 53.80, 19.35. ESI-HRMS (*m/z*) [*M*+*H*]⁺, calcd. 192.1388; found 192.1402. (*M* = C₁₂H₁₇NO)




1-Benzylpiperidine¹³ (5i): Colorless oil, 74.70 mg (85%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.31 – 7.25 (m, 5H), 3.47 (s, 2H), 2.37 (br s, 4H), 1.60 – 1.54 (m, 4H), 1.45 – 1.39 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 138.77, 135.83, 129.39, 128.23, 126.96, 64.05, 54.64, 26.13, 24.54. GC-MS (m/z), calcd. 175.13; found 175.15. (M= C₁₂H₁₇N)




N-benzyl-N-methylaniline¹³ (5j): Yellow liquid, 70.32 mg (71%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.33 – 7.30 (m, 2H), 7.25 – 7.20 (m, 5H), 6.77 – 6.70 (m, 3H), 4.54 (s, 2H), 3.02 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 149.91, 139.18, 129.32, 128.70, 126.99, 126.88, 116.67, 112.50, 56.78, 38.64. ESI-HRMS (m/z) [M+H]⁺, calcd. 198.1283; found 198.1167. (M= C₁₄H₁₅N)




N-benzyl-4-ethyl-N-methylaniline¹⁷ (5k): Yellow liquid, 79.65 mg (70%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.25 – 7.21 (m, 2H), 7.18 – 7.14 (m, 3H), 6.98 (d, *J* = 8.5 Hz, 2H), 6.64 (d, *J* = 8.1 Hz, 2H), 4.41 (s, 2H), 2.90 (s, 3H), 2.48 (q, *J* = 7.6 Hz, 2H), 1.12 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 148.13, 139.45, 132.55, 128.65, 127.00 (d), 112.84, 57.21, 38.79, 27.92, 16.02.



N-benzyl-4-fluoro-N-methylaniline¹⁷ (5l): Yellow liquid, 78.56 mg (73%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.33 – 7.30 (m, 2H), 7.26 – 7.21 (m, 3H), 6.94–6.88 (m, 2H), 6.69–6.66 (m, 2H), 4.46 (s, 2H), 2.96 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 155.84, 153.50, 145.59, 137.89, 127.71, 126.11, 126.01, 114.74, 114.52, 112.86 (d), 56.69, 38.22. ¹⁹F NMR (377 MHz, CDCl₃) δ (ppm) = -129.09. ESI-HRMS (m/z) [M+H]⁺, calcd. 216.1189; found 216.1091. (M= C₁₄H₁₄FN)




N-benzyl-1-(furan-2-yl)-N-methylmethanamine¹⁸ (5m): Colorless viscous liquid, 82.78 mg (82%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.41 (br s, 1H), 7.35–7.27 (m, 5H), 6.34 (m, 1H), 6.22 (d, *J* = 3.1 Hz, 1H), 3.59 (s, 2H), 3.55 (s, 2H), 2.25 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 152.62, 142.16, 138.83, 129.26, 128.39, 127.18, 110.18, 108.68, 61.32, 53.40, 42.13. ESI-HRMS (m/z) [M+H]⁺, calcd. 202.1232; found 202.1185. (M= C₁₃H₁₅NO)




N-benzyl-N-methyl-1-phenylmethanamine¹⁸ (5n): Colorless oil, 91.52 mg (86%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.30 – 7.15 (m, 10H), 3.45 (s, 4H), 2.11 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 139.49, 129.07, 128.36, 127.06, 62.01, 42.39. ESI-HRMS (m/z) [M+H]⁺, calcd.

212.1439; found 212.1479. (M= C₁₅H₁₇N)




N-allyl-N-benzylaniline¹⁹ (5o): Colorless viscous liquid, 62.78 mg (56%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.31 – 7.22 (m, 5H), 7.18-7.14 (m, 2H) 6.71 – 6.65 (m, 3H), 5.90 – 5.82 (m, 1H), 5.20 – 5.15 (m, 2H), 4.53 (s, 2H), 3.99 (d, *J* = 4.8 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 149.10, 139.10, 133.80, 129.28, 128.72, 126.95, 126.74, 116.65, 116.47,

112.54, 54.10, 53.19. ESI-HRMS (m/z) [M+H]⁺, calcd. 224.1439; found 224.1357. (M= C₁₆H₁₇N)




4-(cyclopropylmethyl)morpholine hydrochloride (5p): White solid, 51.23 mg (72%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 13.00 (s, 1H), 4.33 (t, *J* = 12.3 Hz, 2H), 3.98 (d, *J* = 10.9

Hz, 2H), 3.55 (d, *J* = 11.9 Hz, 2H), 2.91 (br s, 4H), 1.37-1.31 (m, 1H), 0.80 (q, *J* = 5.5 Hz, 2H), 0.45 (q, *J* = 5.2 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 63.77, 62.49, 51.68, 5.13, 5.00. ESI-HRMS (m/z) [M-Cl]⁺, calcd. 142.1232; found 142.1232. (M= C₈H₁₆NO)




1-butylmorpholine hydrochloride (5q): White solid, 68.24 mg (94%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 13.05 (s, 1H), 4.33 (t, *J* = 12.3 Hz, 2H), 3.96 (d, *J* = 11.7 Hz, 2H), 3.43 (d, *J* = 11.6 Hz, 2H), 2.95 – 2.84 (m, 4H), 1.90 (br s, 2H), 1.46 – 1.37 (m, 2H), 0.97 (t, *J* = 7.3 Hz, 3H). ¹³C NMR

(101 MHz, CDCl₃) δ (ppm) = 63.76, 58.04, 52.00, 25.23, 20.24, 13.65. ESI-HRMS (m/z) [M-Cl]⁺, calcd. 144.1388; found 144.1421. (M= C₈H₁₈NO)




1-methylpyrrolidine hydrochloride (5r): White solid, 39.86 mg (93%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 12.31 (s, 1H), 3.74 (br s, 2H), 2.83 (d, *J* = 4.6 Hz, 3H), 2.81-2.76 (m, 2H), 2.19 – 2.04 (m, 4H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 55.45,

41.08, 23.82. ESI-HRMS (m/z) [M-Cl]⁺, calcd. 86.0970; found 86.0692. (M= C₅H₁₂N)




1-methylpiperidine hydrochloride (5s): White solid, 43.82 mg (92%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 12.16 (s, 1H), 3.46 (d, *J* = 11.1 Hz, 2H), 2.73 (d, *J* = 4.4 Hz, 3H), 2.65 (dd, *J* = 21.8, 10.5 Hz, 2H), 2.23 (q, *J* = 12.9 Hz, 2H), 1.86 (t, *J* = 17.6 Hz, 3H), 1.43 – 1.32 (m, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 55.25,

44.08, 22.86, 21.65. ESI-HRMS (m/z) [M-Cl]⁺, calcd. 100.1126; found 100.0781. (M= C₆H₁₄N)




C₈H₁₇N)

1-methylazocane hydrochloride (5u): White solid, 66.43 mg (85%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 11.94 (s, 1H), 3.46 (br s, 2H), 2.99 (br s, 2H), 2.76 (s, 3H), 2.0 – 1.54 (m, 10H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 52.77, 43.25, 26.20, 24.24, 22.50. ESI-HRMS (m/z) [M-Cl]⁺, calcd. 128.1439; found 128.1131. (M=




N-(4-(tert-butyl)benzyl)-N-methyl-1-(naphthalen-1-yl)methanamine (Butenafine)²⁰ (5x): Colorless oily liquid (115.13, 72%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 8.41 (d, *J* = 8.0 Hz, 1H), 7.97 (d, *J* = 7.9 Hz, 1H), 7.90 (d, *J* = 8.2 Hz, 1H), 7.66 – 7.59 (m, 3H), 7.56 – 7.44 (m, 5H), 4.08 (s, 2H), 3.73 (s, 2H), 2.36 (s, 3H),

1.48 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 149.93, 136.36, 135.13, 134.03, 132.68, 128.92, 128.47, 128.01, 127.50, 125.75, 125.65, 125.19 (d), 125.02, 62.14, 60.54, 42.48, 34.55, 31.55. ESI-HRMS (m/z) [M+H]⁺, calcd. 318.2222; found 318.2265. (M= C₂₃H₂₇N)




1-(3,3-diphenylpropyl)piperidine (Fenpiprane)²¹ (5y): Colourless oily liquid, 123.86 mg (88%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.29 – 7.14 (m, 10H), 3.97-3.94 (m, 1H), 2.36 (br s, 4H), 2.30 – 2.25 (m, 4H), 1.62 – 1.56 (m, 4H), 1.45 – 1.42 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 145.04, 128.55, 127.98, 126.24, 57.92, 54.80, 49.53, 32.83, 26.05,

24.55. ESI- HRMS (m/z) [M+H]⁺, calcd. 280.2065; found 280.2083. (M= C₂₀H₂₅N)



6-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine (Ticlopidine)²¹ (5z): Colorless oily liquid, 114.42 mg (86%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.50 (dd, *J* = 7.5, 1.7 Hz, 1H), 7.31 (dd, *J* = 7.7, 1.5

Hz, 1H), 7.21-7.12 (m, 2H), 7.01 (d, *J* = 5.1 Hz, 1H), 6.65 (d, *J* = 5.1 Hz, 1H), 3.78 (s, 2H), 3.59 (s, 2H), 2.85 – 2.80 (m, 4H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 136.16, 134.37, 133.96, 133.52, 130.78, 129.57, 128.34, 126.85, 125.37, 122.76, 58.52, 53.19, 50.84, 25.61. ESI-HRMS (m/z) [M+H]⁺, calcd. 264.0614; found 264.0623 (M= C₁₄H₁₄ClNS)




1-((4-chlorophenyl)(phenyl)methyl)-4-(3-methylbenzyl)piperazine (Meclizine)²¹ (5z'): Off white solid, 167.37 mg (85%). ¹H NMR (400 MHz, CDCl₃) δ 7.38-5.35 (m, 4H), 7.29 – 7.21 (m, 4H), 7.20 – 7.05 (m, 5H), 4.23 (s, 1H), 3.50 (s, 2H), 2.50-2.43 (m, 8H), 2.34 (s, 3H); ¹³C NMR (101 MHz,

CDCl₃) δ (ppm) = 142.29, 141.50, 137.84, 132.57, 130.11, 129.32, 128.70, 128.64, 128.15, 127.97, 127.90,


127.19, 126.49, 75.52, 63.14, 53.40, 51.83, 21.48. ESI-HRMS (m/z) $[M+H]^+$, calcd. 391.1941; found 391.1951 ($M = C_{25}H_{27}ClN_2$)

10. Typical Procedure for Catalytic Desulfurization of Tertiary Thioamides




Inside a N_2 filled glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **1** (3.53 mg, 1 mol%), **6a** (83.2 mg, 0.503 mmol). 1 mL of dry toluene was added followed by the addition of phenylsilane (59.9 mg, 0.553 mmol) and the closed vessel was heated at 60 °C for 12 hours. After completion of reaction, solution was cooled down to room temperature and mesitylene (0.503 mmol) was added as internal standard and product NMR yield was analyzed using 1H NMR in $CDCl_3$ as the solvent. In all cases, the product peaks were integrated with respect to the $-CH-$ peak of the internal standard mesitylene which was normalized to 3. The solution was passed through small pad of celite and concentrated under reduced pressure. The residue was purified by column chromatography using silica/neutral alumina in EtOAc/ hexane mixture as the eluent.


11. Characterization of Amine Products Derived from Tertiary Thioamides




N,N-dimethyl-1-(p-tolyl)methanamine (7b): Colorless liquid, 67.86 mg (90%). 1H NMR (400 MHz, $CDCl_3$) δ (ppm) = 7.21 (d, $J = 7.4$ Hz, 2H), 7.13 (d, $J = 7.5$ Hz, 2H), 3.45 (s, 2H), 2.34 (s, 3H), 2.26 (s, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ (ppm) = 134.27, 129.46, 129.19, 127.88, 63.86, 45.02, 21.27.




1-(2-methoxyphenyl)-N,N-dimethylmethanamine (7c): Colorless liquid, 76.68 mg, (92%). 1H NMR (400 MHz, $CDCl_3$) δ (ppm) = 7.38 – 7.33 (m, 2H), 7.02–6.94 (m, 2H), 3.90 (s, 3H), 3.62 (s, 2H), 2.39 (s, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ (ppm) = 158.11, 131.49, 128.94, 120.45, 110.64, 57.60, 55.62, 45.12.



1-(3,4-dimethoxyphenyl)-N,N-dimethylmethanamine (7d): Colorless liquid, 87.49 mg, (89%). ^1H NMR (400 MHz, CDCl_3) δ (ppm) = 6.92 (s, 1H), 6.80 (s, 2H), 3.87 (d, J = 8.2 Hz, 6H), 3.40 (s, 2H), 2.25 (s, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ (ppm) = 149.09, 148.40, 121.50, 112.31, 110.85, 64.13, 56.02 (d), 45.15.




1-(3-chlorophenyl)-N,N-dimethylmethanamine (7e): Colorless liquid, 76.98 mg, (90%). ^1H NMR (400 MHz, CDCl_3) δ (ppm) = 7.35 (s, 1H), 7.27 (d, J = 1.3 Hz, 3H), 3.51 (s, 2H), 2.32 (s, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ (ppm) = 134.49, 129.91, 129.52, 127.96, 127.64, 63.37, 44.98.




1-(3-bromophenyl)-N,N-dimethylmethanamine (7f): Colorless liquid, 97.63 mg, (91%). ^1H NMR (400 MHz, CDCl_3) δ (ppm) = 7.50 (s, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.27 (d, J = 7.4 Hz, 1H), 7.20 (t, J = 7.7 Hz, 1H), 3.43 (s, 2H), 2.27 (s, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ (ppm) = 140.85, 132.22, 130.52, 130.04,


127.87, 122.63, 63.67, 45.30.




N,N-dimethyl-1-(thiophen-2-yl)methanamine (7g): Colorless liquid, 58.87 mg, (83%). ^1H NMR (400 MHz, CDCl_3) δ (ppm) = 7.25 (dd, J = 5.0, 1.3 Hz, 1H), 6.96-6.92 (m, 2H), 3.68 (s, 2H), 2.30 (s, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ (ppm) = 126.61, 126.44, 125.33, 58.25, 44.99.



1-benzylpyrrolidine (7h): Colorless liquid, 75.62 mg, (93%). ^1H NMR (400 MHz, CDCl_3) δ (ppm) = 7.32-7.21 (m, 5H), 3.61 (s, 2H), 2.51 (s, 4H), 1.76 (s, 4H); ^{13}C NMR (101 MHz, CDCl_3) δ (ppm) = 139.04, 129.13, 128.38, 127.12, 60.77, 54.22, 23.54.




1-(4-methoxybenzyl)pyrrolidine (7i): Colorless liquid, 73.82 mg, (91%). ^1H NMR (400 MHz, CDCl_3) δ (ppm) = 7.26 (d, J = 7.7 Hz, 2H), 6.85 (d, J = 7.6 Hz, 2H), 3.80 (s, 3H), 3.58 (s, 2H), 2.52 (s, 4H), 1.79 (s, 4H); ^{13}C NMR (101 MHz, CDCl_3) δ (ppm) = 158.79, 131.20, 130.28, 113.74, 60.07, 55.37, 54.09, 23.50.



1-(3,4-dimethoxybenzyl)pyrrolidine (7j): Colorless liquid, 98.23 mg, (88%). ^1H NMR (400 MHz, CDCl_3) δ (ppm) = 6.92 (d, J = 9.0 Hz, 1H), 6.86-6.79 (m, 2H), 3.88 (d, J = 9.0 Hz, 6H), 3.57 (s, 2H), 2.52 (s, 4H), 1.81 – 1.78 (m, 4H); ^{13}C NMR (101 MHz, CDCl_3) δ (ppm) = 148.99, 148.18,


121.13, 112.28, 110.93, 60.62, 56.05 (d), 54.23, 23.57.

12. Typical Procedure for Catalytic Desulfurizative Hydrogenation of Primary Thioamides




Inside a N₂ filled glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **1** (3.53 mg, 1 mol%), **8a** (0.503 mmol). 1.5 mL of dry toluene was added followed by the addition of phenylsilane (54.43 mg, 0.503 mmol) and the closed vessel was heated at 100 °C for 16 hours. After completion of reaction, solution was cooled down to room temperature. 0.5 mL of CHCl₃ and mesitylene (0.503 mmol) was added as internal standard and product NMR yield was analyzed using ¹H NMR in CDCl₃ as the solvent. In all cases, the product peaks were integrated with respect to the -CH- peak of the internal standard mesitylene which was normalized to 3. The residue was purified by column chromatography using neutral alumina in EtOAc/ hexane mixture as the eluent.


13. Characterization of Nitrile Products Derived from Primary Thioamides




4-methylbenzonitrile²² (9a): Beige solid, 52.63 mg, (89 %). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.67 (d, *J* = 8.2 Hz, 2H), 7.40 (d, *J* = 8.0 Hz, 2H), 2.55 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 143.78, 132.11, 129.92, 119.23, 109.39, 21.90.




Benzonitrile²² (9b): Colorless oil, 46.33 (89%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.67-7.58 (m, 3H), 7.49-7.45 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 132.89, 132.28, 129.24, 118.96, 112.58.



4-methoxybenzonitrile²² (9d): White Solid, 59.32 mg (88%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 7.58 (d, *J* = 8.9 Hz, 2H), 6.95 (d, *J* = 8.9 Hz, 2H), 3.85 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 162.96, 134.10, 119.34, 114.87, 104.09, 55.66.




4-chlorobenzonitrile²² (9e): White Solid, 57.57 mg (83%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J* = 8.4 Hz, 2H), 7.47 (d, *J* = 8.5 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 139.71, 133.53, 129.85, 118.11, 110.95.



1-naphthonitrile²³ (9f): Pale Yellow liquid, 65.73 mg (85%). ¹H NMR (400 MHz, CDCl₃) δ (ppm) = 8.20 (dd, *J* = 8.0, 5.2 Hz, 1H), 8.06 – 8.02 (m, 1H), 7.88 (dd, *J* = 13.4, 7.8 Hz, 2H), 7.68 – 7.57 (m, 2H), 7.48 (dd, *J* = 14.4, 6.9 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) = 133.31, 132.92, 132.62, 132.33, 128.69, 128.61, 127.57, 125.10 (d), 124.94, 117.85, 110.15.

14. Control Experiments

14.1. Evaluating the role of appended Lewis basic arm



Inside a N₂ filled glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **2** (3.12 mg, 1 mol%) and **4a** (75 mg, 0.503 mmol). 1 mL of dry toluene was added followed by the addition of phenylsilane (59.9 mg, 0.553 mmol) and the closed vessel was heated at 80° C for 36 hours. The solution was cooled to room temperature, and 70 μ L of mesitylene (60.5 mg, 0.503 mmol) was added as an internal standard. The yield was analyzed using ¹H NMR in CDCl₃, which yielded 0.452 mmol (90%) of desired deoxygenated amine product **5a**.






Figure S4. ¹H NMR spectrum of deoxygenative hydrogenation of **4a** catalyzed by complex **2** in CDCl₃ (Table S1, entry 21)

14.2. Evaluating the role of appended Lewis acidic boron arm

14.2.1. Catalytic reaction of amide 4a using complex 3



Inside a glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **3** (2.97 mg, 1 mol%) and **4a** (75 mg, 0.503 mmol). 1 mL of dry toluene was added followed by the addition of phenylsilane (59.9 mg, 0.553 mmol) and the closed vessel was heated at 80 °C for 36 hours. The solution was cooled to room temperature and 70 μ L of mesitylene (60.5 mg, 0.503 mmol) was added as internal standard and yield was analyzed using ¹H NMR in CDCl₃, which yielded 0.191 mmol (38%) of desired deoxygenated amine product **5a**.







Figure S5. Deoxygenative hydrogenation of **4a** catalyzed by complex **3** (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (Table S1, entry 22)

14.2.2. Catalytic reaction of amide **4a** using complex **3** and external $\text{Ph}(\text{CH}_2)_2\text{Bpin}$



A 25 mL pressure tube equipped with a magnetic stirring bar was charged with **3** (2.97 mg, 1 mol%), $\text{Ph}(\text{CH}_2)_2\text{Bpin}$ (5.84 mg, 5 mol%) **4a** (75 mg, 0.503 mmol). 1 mL of dry toluene was added followed by the addition of phenylsilane (59.9 mg, 0.553 mmol) and the closed vessel was heated at 80°C for 36 hours. The solution was cooled to room temperature and 70 μL of mesitylene (60.5 mg, 0.503 mmol) was added as internal standard and yield was analyzed using ^1H NMR in CDCl_3 which yielded 0.186 mmol (37%) of desired deoxygenated amine product **5a**.







Figure S6. Deoxygenative hydrogenation of **4a** catalyzed by complex **3** and external $\text{Ph}(\text{CH}_2)_2\text{Bpin}$
 (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum

14.2.3. Catalytic reaction of amide **4a** using only $\text{Ph}(\text{CH}_2)_2\text{Bpin}$



A 25 mL pressure tube equipped with a magnetic stirring bar was charged with $\text{Ph}(\text{CH}_2)_2\text{Bpin}$ (5.84 mg, 5 mol%) and **4a** (75 mg, 0.503 mmol). 1 mL of dry toluene was added followed by the addition of phenylsilane (59.9 mg, 0.553 mmol) and the closed vessel was heated at 80°C for 36 hours. The solution was cooled to room temperature and 70 μL of mesitylene (60.5 mg, 0.503 mmol) was added as internal standard and yield was analyzed using ^1H NMR in CDCl_3 , where no amine formation was detected.









Figure S7. Deoxygenative hydrogenation of **4a** catalyzed by $\text{Ph}(\text{CH}_2)_2\text{Bpin}$ (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum

14.3. Catalytic hydrogenation of acetophenone using complex **1**



A 25 mL pressure tube equipped with a magnetic stirring bar was charged with complex **1** (3.5 mg, 1 mol%) and acetophenone (60.5 mg, 0.503 mmol). 1 mL of dry toluene was added, followed by the addition of phenylsilane (59.9 mg, 0.553 mmol), and the closed vessel was heated at 80 °C for 36 hours. The solution was cooled to room temperature and 70 μL of mesitylene (60.5 mg, 0.503 mmol) was added as internal standard and yield was analyzed using ^1H NMR in CDCl_3 which yielded 0.276 mmol (55%) of silylated product along with 0.07 mmol (14%) ethyl benzene as the deoxygenated product. This result further depicted that the boron arm in SCS of complex **1** might be involved in substrate deoxygenation during catalysis.









Figure S8. Deoxygenative hydrogenation of acetophenone catalyzed by complex **1** (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (b) Mass pattern for ethylbenzene (d) Mass pattern for 1-phenylethan-1-ol

15. Homogeneity test using mercury drop experiment



Inside a glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with catalyst **1** (3.53 mg, 1 mol%) and **4a** (0.503 mmol). 1 mL of dry toluene was added followed by the addition of mercury (302.7 mg, 300 equiv. w.r.t. **1**) and phenylsilane (0.553 mmol). The tube was sealed properly and brought out of the glove box and heated at 80 °C for 36 hours. The solution was cooled to room temperature and mesitylene (0.503 mmol) was added as the internal standard and aliquot was analyzed using ¹H NMR in CDCl₃ which yielded 0.452 mmol (90%) of desired deoxygenated amine product **5a**. This result confirms the homogeneous behavior of catalyst **1** towards deoxygenative hydrogenation.






Figure S9. Deoxygenative hydrogenation of **4a** catalyzed by complex **1** in presence of Hg (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (Table S1, entry 20)

16. Mechanistic Studies

16.1. Generation of [Ru-H] species using complex **1**

Inside a glove box, in a pre-dried NMR tube, 1:1 mixture of **1** (0.0163 mmol) and PhSiH_3 (0.0163 mmol) in 0.6 mL C_6D_6 or CDCl_3 was added and the tube was brought out of the glove box and heated for 1 hour at 50 $^\circ\text{C}$ and then subjected to ^1H NMR analysis to observe the [Ru-H] species.




Figure S10. ^1H NMR spectrum for [Ru-H] species observed after reaction of **1** with PhSiH_3 in CDCl_3




Figure S11. ^1H NMR spectrum for **[Ru-H]** species observed after reaction of **1** with PhSiH_3 in C_6D_6






Figure S12. ESI-HRMS spectrum of Ru-H intermediate (**A**)

16.2. Stoichiometric reaction of in-situ generated Ru-H intermediate with amide 4a



Inside a glove box, in a pre-dried NMR tube, at first, a 1:1 mixture of **1** (0.017 mmol) and PhSiH_3 (0.017 mmol) in 0.6 mL C_6D_6 was added and the tube was brought out of the glove box and heated for 1 hour at 50°C and then subjected to ^1H NMR analysis which depicted a singlet peak at -11.08 ppm which corresponds to intermediate (A). The same tube was brought inside the glove box and amide **4a** (0.017 mmol) was added and ^1H NMR was analyzed first at RT, which showed a small amount of amine **5a** formation. Further, the solution was heated at 80°C for 1 hour and analyzed by ^1H NMR, where almost complete amine **5a** formation was observed.







Figure S13. (a) ^1H NMR of 1:1 mixture of complex **1** and PhSiH_3 (b) After 1 equiv. of amide **4a** addition at RT (c) After heating the same solution at 80°C for 1 hour

16.3. Catalytic reaction of in-situ generated Ru-H intermediate (A) with amide **4a** using a fewer equiv. of PhSiH₃



Inside a glove box, in a pre-dried NMR tube, at first, a 1:1 mixture of **1** (7.02 mg, 1 mol% w.r.t. amide **4a**) and PhSiH₃ (1.08 mg, 1 mol% w.r.t. amide **4a**) in 0.5 mL C₆D₆ was added and the tube was brought out of the glove box and heated for 1 hour at 50 °C and then subjected to ¹H NMR analysis which depicted a singlet peak at -11.08 ppm which corresponds to intermediate (A). Inside a glove box, the in-situ generated intermediate (A) was transferred to a 25 mL pressure tube containing amide **4a** (149.19 mg, 1 equiv.), PhSiH₃ (54.11 mg, 0.5 equiv. w.r.t. **4a**) and dry toluene (0.5 mL). The tube was brought out of the glove box and heated at 80 °C for 36 hours in an oil bath. Mesitylene (69.6 μL, 0.5 equiv. w.r.t. **4a**) was added and ¹H NMR was analyzed, where 43% NMR yield of amine **5a** formation was observed.





Figure S14. ¹H NMR spectrum of crude reaction mixture in CDCl₃ for deoxygenative hydrogenation of **4a** catalyzed by in-situ generated Ru-H intermediate (A) with a fewer equiv. of PhSiH₃

16.4. Variable Temperature (VT) NMR study for the detection of appended boron-substrate interaction in complex **1**

16.4.1. Variable Temperature (VT) NMR study of complex **1** and complex **1** +amide **4a**

In a pre-dried NMR tube, a 1:10 mixture of **1** (0.021 mmol), **4a** (0.213 mmol), and 0.6 mL acetone- d_6 was added and variable temperature NMR study was performed from 25 °C to -40 °C. However, no such significant shifting of protons of appended boron ^1H and ^{11}B was observed under the measured NMR temperature scale.



(b)





Figure S15. Variable temperature (VT) NMR of only complex **1** in acetone- d_6 (a) ^1H NMR spectrum measured from 25 °C to -40 °C (b) ^{11}B NMR spectrum measured from 25 °C to -40 °C







Figure S16. Variable temperature (VT) NMR of a mixture of complex **1** and amide **4a** in acetone- d_6 (a) ^1H NMR spectrum measured from 25 °C to -40 °C (b) ^{11}B NMR spectrum measured from 25 °C to -40 °C

16.4.2. Variable Temperature (VT) NMR study using dimethylaminopyridine (DMAP) and complex **1**



In a pre-dried NMR tube, a 1:5 mixture of **1** (0.014 mmol), dimethylaminopyridine (DMAP) (0.071 mmol), and 0.6 mL acetone- d_6 was added and variable temperature NMR study was performed from 25 °C to -40 °C. The ^1H NMR analysis revealed a significant up-field shift (shielding) of methylene protons ($-\text{CH}_2$) adjacent to the $-\text{Bpin}$ arm from 0.91 ppm to 0.47 ppm with a gradual decreasing the temperature from 25 °C to -40 °C. The ^{11}B NMR spectrum also showed a significant up-field shift of peak signal from 32.30 ppm to 12.80 ppm at -40 °C. These results revealed the formation of adduct between appended boron of complex **1** and DMAP.²⁴





Figure S17. Variable temperature (VT) NMR of a mixture of complex **1** and DMAP in acetone- d_6 (a) ^1H NMR spectrum measured from 25 °C to -40 °C (b) ^{11}B NMR spectrum measured from 25 °C to -40 °C

16.5. ESI-HRMS control experiment of stoichiometric reaction of a 1:1:1 mixture of complex **1**, PhSiH₃ and **4a**

Inside a glove box, in a 10 mL pressure tube, a 1:1:1 mixture of **1** (10 mg, 0.014 mmol) and PhSiH₃ (1.54 mg, 0.014 mmol), amide **4a** (2.12 mg, 0.014 mmol) and 0.6 mL of dry toluene was added and the tube was brought out of the glove box and heated for 10 minutes at 60 °C. A little aliquot was submitted for ESI-HRMS mass analysis. Mass analysis showed the complete formation of amine **5a** as a peak signal at $[M+H]^+$, $m/z = 136.1124$ [$M = C_9H_{13}N$] was observed along with the presence of active Ru-H intermediate (**A**) at $[1-2Cl+H]^+$ ($m/z = 633.2906$) [$1 = C_{32}H_{47}BCl_2N_4O_2Ru$]. Moreover, the presence of peak signal at $[1-Cl+5a]^+$, ($m/z = 802.3511$) was also observed, which is assigned as amine **5a** coordinated Ru-complex **1**.








Figure S18. ESI-HRMS analysis spectrum of a 1:1:1 mixture of complex **1**, PhSiH₃ and **4a**

16.6. Identification of siloxane by-product



Inside a glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **1** (3.53 mg, 1 mol%) and **4a** (0.503 mmol). 1 mL of dry toluene was added followed by the addition of phenylsilane (0.553 mmol) and the closed vessel was heated at 80 °C for 36 hours. The solution was cooled to room temperature and a little aliquot was analyzed using ESI-HRMS in acetonitrile solvent which showed the formation of phenyl disiloxane with a peak signal, $m/z = 269.1634$ assigned as $[M+K]^+$. ($M = C_{12}H_{14}OSi_2$) along with the polysiloxanes.²⁵

17. ^1H NMR monitoring of **5a** formation with progress of time



Inside the glove box, in a pre-dried NMR tube, **4a** (1 equiv., 0.503 mmol), catalyst **1** (1 mol %), 0.6 mL of C_6D_6 and followed by PhSiH_3 (1.1 equiv., 0.553 mmol) were added and the tube was brought out of the glove box and ^1H NMR was measured in different intervals of time from RT- 8 hours after heating at 80°C in an oil bath. It was observed that with the progress of time, the formation of **5a** gradually increased with the decrease in the concentration of amide **4a** and phenylsilane.




Figure S20. ^1H NMR spectrum of NMR tube experiment for the progress of **5a** formation measured in intervals of RT-8 hours in C_6D_6

18. Spectroscopic data




Figure S21. ¹H NMR spectrum of 2-bromo-6-(piperidine-1-yl)pyridine in CDCl₃




Figure S22. ¹³C NMR spectrum of 2-bromo-6-(piperidine-1-yl)pyridine in CDCl₃




Figure S23. 135-DEPT NMR spectrum of 2-bromo-6-(piperidine-1-yl)pyridine in CDCl_3




Figure S24. ^1H NMR spectrum of 2-(1H-imidazol-1-yl)-6-(piperidin-1-yl)pyridine in CDCl_3




Figure S25. ¹³C NMR spectrum of 2-(1H-imidazol-1-yl)-6-(piperidin-1-yl)pyridine in CDCl₃




Figure S26. ESI-HRMS of 2-(1H-imidazol-1-yl)-6-(piperidin-1-yl)pyridine in methanol




Figure S27. ¹H NMR spectrum of **L1** in CDCl₃




Figure S28. ¹³C NMR spectrum of **L1** in CDCl₃




Figure S29. 135-DEPT NMR spectrum of **L1** in CDCl_3




Figure S30. ^{11}B NMR spectrum of **L1** in CDCl_3




Figure S31. ESI-HRMS of **L1** in acetonitrile




Figure S32. IR Spectrum of **L1**




Figure S33. ¹H NMR spectrum of **L2** in CDCl₃




Figure S34. ¹³C NMR spectrum of **L2** in CDCl₃




Figure S35. $^{135}\text{DEPT}$ NMR spectrum of **L2** in CDCl_3




Figure S36. ^{11}B NMR spectrum of **L2** in CDCl_3




Figure S37. ESI-HRMS of **L2** in acetonitrile




Figure S38. IR Spectrum of **L2**




Figure S39. ^1H NMR spectrum of **L3** in CDCl_3




Figure S40. ^{13}C NMR spectrum of **L3** in CDCl_3




Figure S41. 135-DEPT NMR spectrum of **L3** in CDCl_3




Figure S42. ESI-HRMS of **L3** in acetonitrile




Figure S43. IR Spectrum of **L3**




Figure S44. ^1H NMR spectrum of complex **1** in CDCl_3




Figure S45. ^{13}C NMR spectrum of complex **1** in CDCl_3




Figure S46. $^{135}\text{-DEPT}$ NMR spectrum of complex **1** in CDCl_3




Figure S47. ^{11}B NMR spectrum of complex **1** in CDCl_3




Figure S48. ESI-HRMS of complex **1** in acetonitrile




Figure S49. Isotopic mass distribution analysis of complex **1**. Simulated (a) and Experimental (b)




Figure S50. IR spectrum of complex **1**




Figure S51. HSQC spectrum of complex **1** in CDCl_3




Figure S52. ^1H NMR spectrum of complex **1-PF₆** in CDCl_3




Figure S53. ^{13}C NMR spectrum of complex **1-PF₆** in CDCl_3




Figure S54. $^{135}\text{-DEPT}$ NMR spectrum of complex **1-PF₆** in CDCl_3




Figure S55. ^{11}B NMR spectrum of complex **1-PF₆** in CDCl_3




Figure S56. ^{31}P NMR spectrum of complex **1-PF₆** in CDCl_3




Figure S57. ^{19}F NMR spectrum of complex **1-PF₆** in CDCl_3




Figure S58. ESI-HRMS of complex **1-PF₆** in acetonitrile ($\text{M} = \text{C}_{32}\text{H}_{47}\text{BClF}_6\text{N}_4\text{O}_2\text{PRu}$)




Figure S59. Isotopic mass distribution analysis of complex **1-PF₆**. Simulated (a) and Experimental (b) (**M**= C₃₂H₄₇BClF₆N₄O₂PRu)




Figure S60. HSQC spectrum of complex **1-PF₆** in CDCl₃




Figure S61. ^1H NMR spectrum of complex **2** in DMSO- d_6




Figure S62. ^{13}C NMR spectrum of complex **2** in DMSO- d_6




Figure S63. 135-DEPT NMR spectrum of complex **2** in DMSO-d₆




Figure S64. ¹¹B NMR spectrum of complex **2** in DMSO-d₆




Figure S65. ESI-HRMS of complex **2** in acetonitrile




Figure S66. Isotopic mass distribution analysis of complex **2**. Simulated (a) and Experimental (b)




Figure S67. IR spectrum of complex 2




Figure S68. ¹H NMR spectrum of complex 3 measured in CDCl₃




Figure S69. ¹³C NMR spectrum of complex **3** measured in CDCl₃




Figure S70. ¹³⁵ DEPT NMR spectrum of complex **3** measured in CDCl₃




Figure S71. ESI-HRMS of complex **3** in acetonitrile




Figure S72. Isotopic mass distribution analysis of complex **3**. Simulated (a) and Experimental (b)




Figure S73. IR spectrum of complex **3**




Figure S74. HSQC spectrum of complex **3** in CDCl_3




Figure S75. ¹H NMR spectrum of complex **1**-BF₄ measured in CDCl₃




Figure S76. ¹³C NMR spectrum of complex **1**-BF₄ measured in CDCl₃




Figure S77. ^{11}B NMR spectrum of complex **1-BF₄** measured in CDCl_3




Figure S78. ^{19}F NMR spectrum of complex **1-BF₄** in CDCl_3




Figure S79. Isotopic mass distribution analysis of complex **1-BF₄**. Simulated (a) and Experimental (b) measured in acetonitrile






Figure S80. ESI-HRMS mass spectrum for **BF₄⁻** counter anion measured in acetonitrile



% Conversion of **4a** = 100%, % Yield of **5a** = 97%







Figure S81. Spectral data for deoxygenative hydrogenation of **4a** to **5a** by **1** (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (c) Mass pattern for **5a** (Table S1, entry 9)



% Conversion of **4a** = 100%, % Yield of **5a** = 94%

(b)





Figure S82. Spectral data for deoxygenative hydrogenation of **4a** to **5a** by **1-PF₆** (a) ¹H NMR in CDCl₃ (b) GC-MS spectrum (Table S1, entry 23)



% conversion of **4a** = 78.5 %, % yield of **5a** = 75%





Figure S83. Spectral data for deoxygenative hydrogenation of **4a** to **5a** by **1** at 60 °C (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (Table S1, entry 11)



% Conversion of **4a** = 92.6 %, % yield of **5a** = 88%





Figure S84. Spectral data for deoxygenative hydrogenation of **4a** to **5a** by **1** for 24 hours (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (Table S1, entry 10)



% Conversion of **4a** = 58%, % yield of **5a** = 55%

(b)





Figure S85. Spectral data for deoxygenative hydrogenation of **4a** to **5a** by **1** using diphenylsilane (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (Table S1, entry 12)



% Conversion of **4a** = 0%





Figure S86. Spectral data for deoxygenative hydrogenation of **4a** to **5a** by **1** using triethylsilane (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (Table S1, entry 13)



% Conversion of **4a** = 63%, % yield of **5a** = 61%





Figure S87. Spectral data for deoxygenative hydrogenation of **4a** to **5a** by **1** using THF as the solvent
 (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (Table S1, entry 15)



% Conversion of **4a** = 39.9%, % yield of **5a** = 33%





Figure S88. Spectral data for deoxygenative hydrogenation of **4a** to **5a** by **1** using 1,4-dioxane as the solvent (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (Table S1, entry 16)



% yield of **5a** = 0





Figure S89. Spectral data for deoxygenative hydrogenation of **4a** to **5a** in absence of catalyst (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (Table S1, entry 18)








Figure S90. Spectral data for deoxygenative hydrogenation of **4a** to **5a** (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (Table S1, entry 19)



% amine **5a** formation = 96%

Figure S91. ^1H NMR Spectral data for deoxygenative hydrogenation of **4a** to **5a** using complex **1-BF₄** in CDCl_3 (Table S1, entry 24)



% Conversion of **6a** = 98.33%, % yield of **5a** = 98%






Figure S92. Spectral data for deoxygenative hydrogenation of **6a** to **5a** (a) ¹H NMR in CDCl₃ (b) GC-MS spectrum (Table S2, entry 5)



% yield of **9a** = 94%






Figure S93. Spectral data for dehydrosulfurization of **8a** to **9a** by **1** (a) ^1H NMR in CDCl_3 (b) GC-MS spectrum (c) Mass pattern for **9a** (Table S3, entry 2)




Figure S94. ^1H NMR data measured in CDCl_3 for deoxygenative hydrogenation of **4a** to **5a** with 2 equiv. of PhSiH_3 at 80 °C for 6 h catalyzed by complex **1**




Figure S95. ^1H NMR spectrum of **5a** measured in CDCl_3




Figure S96. ^{13}C NMR spectrum of **5a'** measured in CDCl_3




Figure S97. ESI-HRMS spectrum of **5a'** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S98. ^1H NMR spectrum of **5b** measured in CDCl_3




Figure S99. ¹³C NMR spectrum of **5b** measured in CDCl₃




Figure S100. ¹H NMR spectrum of **5c** measured in CDCl₃




Figure S101. ^{13}C NMR spectrum of **5c** measured in CDCl_3




Figure S102. ^1H NMR spectrum of **5d** measured in CDCl_3




Figure S103. ^{13}C NMR spectrum of **5d** measured in CDCl_3




Figure S104. ESI-HRMS spectrum of **5d** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S105. ¹H NMR spectrum of **5e** measured in CDCl₃




Figure S106. ¹³C NMR spectrum of **5e** measured in CDCl₃




Figure S107. ¹H NMR spectrum of **5f** measured in CDCl₃




Figure S108. ¹³C NMR spectrum of **5f** measured in CDCl₃




Figure S109. ^{19}F NMR spectrum of **5f** measured in CDCl_3




Figure S110. ESI-HRMS spectrum of **5f** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S111. ¹H NMR spectrum of **5g** measured in CDCl₃




Figure S112. ¹³C NMR spectrum of **5g** measured in CDCl₃




Figure S113. ESI-HRMS spectrum of **5g** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S114. ¹H NMR spectrum of **5h** measured in CDCl₃




Figure S115. ^{13}C NMR spectrum of **5h** measured in CDCl_3




Figure S116. ESI-HRMS spectrum of **5h** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S117. ¹H NMR spectrum of **5i** measured in CDCl₃




Figure S118. ¹³C NMR spectrum of **5i** measured in CDCl₃




Figure S119. Mass pattern of GC-MS spectrum of compound **5i**




Figure S120. ^1H NMR spectrum of **5j** measured in CDCl_3




Figure S121. ^{13}C NMR spectrum of **5j** measured in CDCl_3




Figure S122. ESI-HRMS spectrum of **5j** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S123. ¹H NMR spectrum of **5k** measured in CDCl₃




Figure S124. ¹³C NMR spectrum of **5k** measured in CDCl₃




Figure S125. ¹H NMR spectrum of **5l** measured in CDCl₃




Figure S126. ¹³C NMR spectrum of **5l** measured in CDCl₃




Figure S127. ^{19}F NMR spectrum of **5I** measured in CDCl_3




Figure S128. ESI-HRMS spectrum of **5I** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S129. ¹H NMR spectrum of **5m** measured in CDCl₃




Figure S130. ¹³C NMR spectrum of **5m** measured in CDCl₃




Figure S131. ESI-HRMS spectrum of **5m** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S132. ¹H NMR spectrum of **5n** measured in CDCl₃




Figure S133. ^{13}C NMR spectrum of **5n** measured in CDCl_3




Figure S134. ESI-HRMS spectrum of **5n** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S135. ¹H NMR spectrum of **5o** measured in CDCl₃




Figure S136. ¹³C NMR spectrum of **5o** measured in CDCl₃




Figure S137. ESI-HRMS spectrum of **5o** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S138. ^1H NMR spectrum of crude reaction mixture of hydrogenated product **5o'** measured in CDCl_3




Figure S139. ESI-HRMS spectrum of **5o'** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S140. ¹H NMR spectrum of **5p** measured in CDCl₃




Figure S141. ¹³C NMR spectrum of **5p** measured in CDCl₃




Figure S142. ESI-HRMS spectrum of **5p** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S143. ^1H NMR spectrum of **5q** measured in CDCl_3




Figure S144. ¹³C NMR spectrum of **5q** measured in CDCl₃




Figure S145. ESI-HRMS spectrum of **5q** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S146. ¹H NMR spectrum of **5r** measured in CDCl₃




Figure S147. ¹³C NMR spectrum of **5r** measured in CDCl₃




Figure S148. ESI-HRMS spectrum of **5r** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S149. ^1H NMR spectrum of **5s** measured in CDCl_3




Figure S150. ¹³C NMR spectrum of **5s** measured in CDCl₃





Figure S151. ESI-HRMS spectrum of **5s** measured in methanol; (*top*, simulated; *bottom*, experimental)



% NMR yield= 98%

Figure S152. ¹H NMR spectrum of crude reaction mixture of **5t** measured in CDCl₃




Figure S153. ¹H NMR spectrum of **5u** measured in CDCl₃




Figure S154. ^{13}C NMR spectrum of **5u** measured in CDCl_3





Figure S155. ESI-HRMS spectrum of **5u** measured in methanol; (*top*, simulated; *bottom*, experimental)



% NMR Yield= 78%

Figure S156. ¹H NMR spectrum of crude reaction mixture of **5v** measured in CDCl₃




Figure S157. ¹³C NMR spectrum of crude reaction mixture of **5v** measured in CDCl₃




Figure S158. GC-MS spectrum of crude reaction mixture of **5v**




Figure S159. ^1H NMR spectrum of butenafine (**5x**) measured in CDCl_3




Figure S160. ^{13}C NMR spectrum of butenafine (**5x**) measured in CDCl_3




Figure S161. ESI-HRMS spectrum of **5x** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S162. ¹H NMR spectrum of fenpiprane (**5y**) measured in CDCl₃




Figure S163. ¹³C NMR spectrum of fenpiprane (**5y**) measured in CDCl₃




Figure S164. ESI-HRMS spectrum of **5y** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S165. ^1H NMR spectrum of ticlopidine (**5z**) measured in CDCl_3




Figure S166. ^{13}C NMR spectrum of ticlopidine (**5z**) measured in CDCl_3




Figure S167. ESI-HRMS spectrum of **5z** measured in methanol; (*top*, simulated; *bottom*, experimental)




Figure S168. ¹H NMR spectrum of meclizine (**5z'**) measured in CDCl₃




Figure S169. ¹³C NMR spectrum of meclizine (**5z'**) measured in CDCl₃






Figure S170. ESI-HRMS spectrum of **5z'** measured in methanol; (*top*, simulated; *bottom*, experimental)

19. Deoxygenative hydrogenation of secondary amide



Inside a glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **1** (3.53 mg, 1 mol%) and N-Phenylbenzamide (99.2 mg, 0.503 mmol). 1 mL of dry toluene was added followed by the addition of 124 μL of phenylsilane (108.9 mg, 1.006 mmol) and the closed vessel was heated at 100 $^{\circ}\text{C}$ for 36 hours. The solution was cooled to room temperature and 70 μL of mesitylene (60.5 mg, 0.503 mmol) was added as internal standard and yield was analyzed using ^1H NMR in CDCl_3 which yielded 0.291 mmol (58 %) of desired deoxygenated amine product.



NMR Yield of N-Benzylaniline = 58%

Figure S171. ¹H NMR spectrum of deoxygenative hydrogenation of N-phenylbenzamide catalyzed by complex **1** in CDCl₃




Figure S172. GC-MS spectrum of reaction mixture of N-phenylbenzamide hydrogenation




Figure S173. Mass pattern of GC-MS spectrum for N-benzylaniline




Figure S174. ¹H NMR spectrum of **7b** measured in CDCl₃




Figure S175. ¹³C NMR spectrum **7b** measured in CDCl₃




Figure S176. ¹H NMR spectrum of **7c** measured in CDCl₃




Figure S177. ¹³C NMR spectrum **7c** measured in CDCl₃




Figure S178. ¹H NMR spectrum of **7d** measured in CDCl₃




Figure S179. ¹³C NMR spectrum **7d** measured in CDCl₃




Figure S180. ¹H NMR spectrum of **7e** measured in CDCl₃




Figure S181. ¹³C NMR spectrum **7e** measured in CDCl₃




Figure S182. ¹H NMR spectrum of **7f** measured in CDCl₃




Figure S183. ¹³C NMR spectrum **7f** measured in CDCl₃




Figure S184. ¹H NMR spectrum of **7g** measured in CDCl₃




Figure S185. ¹³C NMR spectrum **7g** measured in CDCl₃




Figure S186. ¹H NMR spectrum of **7h** measured in CDCl₃




Figure S187. ¹³C NMR spectrum **7h** measured in CDCl₃





Figure S188. ¹H NMR spectrum of **7i** measured in CDCl₃




Figure S189. ¹³C NMR spectrum **7i** measured in CDCl₃




Figure S190. ¹H NMR spectrum of **7j** measured in CDCl₃





Figure S191. ¹³C NMR spectrum **7j** measured in CDCl₃



% NMR Yield= 94%

Figure S192. ^1H NMR spectrum of crude reaction mixture of **7k** measured in CDCl_3





Figure S193. GC-MS spectrum of crude reaction mixture of **7k**



% NMR Yield= 60%

Figure S194. ^1H NMR spectrum of crude reaction mixture of **7l** measured in CDCl_3





Figure S195. GC-MS spectrum of crude reaction mixture of **7l**



% NMR Yield= 95%

Figure S196. ^1H NMR spectrum of crude reaction mixture of **7m** measured in CDCl_3





Figure S197. GC-MS spectrum of crude reaction mixture of **7m**



% NMR Yield= 86%

Figure S198. ^1H NMR spectrum of crude reaction mixture of **7n** measured in CDCl_3




Figure S199. GC-MS spectrum of crude reaction mixture of **7n**




Figure S200. ¹H NMR spectrum of **9a** measured in CDCl₃




Figure S201. ¹³C NMR spectrum **9a** measured in CDCl₃




Figure S202. ¹H NMR spectrum of **9b** measured in CDCl₃




Figure S203. ¹³C NMR spectrum **9b** measured in CDCl₃




Figure S204. ¹H NMR spectrum of **9d** measured in CDCl₃




Figure S205. ¹³C NMR spectrum **9d** measured in CDCl₃




Figure S206. ¹H NMR spectrum of **9e** measured in CDCl₃




Figure S207. ¹³C NMR spectrum **9e** measured in CDCl₃




Figure S208. ¹H NMR spectrum of **9f** measured in CDCl₃






Figure S209. ¹³C NMR spectrum **9f** measured in CDCl₃

20. Scale-up reaction of deoxygenative hydrogenation of **4a** to **5a** using complex **1**




Inside a N₂ filled glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **1** (21.07 mg, 1 mol%), **4a** (447.57 mg, 3 mmol). 3 mL of dry toluene was added followed by the addition of phenylsilane (357.12 mg, 3.3 mmol) and the closed vessel was heated at 80 °C for 36 hours. After completion of reaction, the solution was cooled down to room temperature and mesitylene (0.5 mmol w.r.t. to **4a**) was added as internal standard and NMR yield was analyzed using ¹H NMR in CDCl₃ as the solvent, which yielded 2.94 mmol of desired amine **5a** (98%).



% amine **5a** formation = 98%

Figure S210. ¹H NMR spectrum of crude reaction measured in CDCl₃ for deoxygenative hydrogenation of **4a** to **5a** with 3 mmol scale reaction catalyzed by complex **1**

21. Dehydrogenation of benzylamine using complex 1



Inside a N₂ filled glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **1** (3.53 mg, 1 mol%), benzylamine (53.9 mg, 0.503 mmol). 1 mL of dry toluene was added followed by the addition of phenylsilane (54.43 mg, 0.503 mmol) and the closed vessel was heated at 100 °C for 16 hours. After completion of the reaction, solution was cooled down to room temperature. 0.5 mL of ethylacetate and mesitylene (0.503 mmol) was added as internal standard and GC-MS analysis was performed, where a major amount of unreacted benzylamine was observed along with the formation of a small amount of dibenzylamine at a retention time of 12.757 min with *m/z*=197.11 and no benzonitrile formation was detected.





Figure S211. GC-MS spectrum of crude reaction for dehydrogenation of benzylamine catalyzed by complex **1**

22. GC-TCD analysis of H₂ gas release during desulfurization of thioamide **8a** to nitrile **9a** using complex **1**



Inside a N₂ filled glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **1** (3.53 mg, 1 mol%), **8a** (76 mg, 0.503 mmol). 1.5 mL of dry toluene was added followed by the addition of phenylsilane (54.43 mg, 0.503 mmol) and the closed vessel was heated at 100 °C for 16 hours. After completion of the reaction, solution was cooled down to room temperature, and 300 µL of evolved gas in the solution was injected into the GC-TCD, which showed the formation of H₂ gas at a retention time of 0.868 min.





Figure S212. GC-TCD spectrum for the detection of H₂ gas

23. Synthetic procedure and characterization data for 1,3-Diphenyldisiloxane

The titled compound was synthesized according to the known literature procedure.²⁶

The characterization data of 1,3-Diphenyldisiloxane are in accordance with the data observed in the literature.^{26,27}



^1H NMR (400 MHz, CDCl_3) δ (ppm) = 7.64 – 7.55 (m, 4H), 7.49-7.39 (m, 6H), 5.17 (s, 4H)

^{13}C NMR (101 MHz, CDCl_3) δ (ppm) = 134.22, 130.67, 128.25

^{29}Si NMR (80 MHz, C_6D_6) δ (ppm) = -25.43.




Figure S213. ^1H NMR spectrum of 1,3-diphenyldisiloxane in CDCl_3




Figure S214. ^{13}C NMR spectrum of 1,3-diphenyldisiloxane in CDCl_3







Figure S215. ^{29}Si NMR spectrum of 1,3-Diphenyldisiloxane in CDCl_3



24. Deoxygenative hydrogenation of **4a** to **5a** using 1,3-diphenyldisiloxane (DPDS) as the hydride source



Inside a N₂ filled glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **1** (1.76 mg, 1 mol%), **4a** (37.5 mg, 0.25 mmol). 0.5 mL of dry toluene was added, followed by the addition of 1,3-diphenyldisiloxane (63.36 mg, 0.275 mmol), and the closed vessel was heated at 80 °C for 36 hours. After completion of the reaction, solution was cooled down to room temperature, and mesitylene (35 μL, 0.25 mmol w.r.t. to **4a**) was added as internal standard and NMR yield was analyzed using ¹H NMR in CDCl₃ as the solvent, which yielded 0.0875 mmol of desired amine **5a** (35%), whereas using 2 equiv. of 1,3-diphenyldisiloxane under the optimized reaction conditions yielded 61% of amine **5a** formation. However, in the absence of a catalyst, using 1.1 equiv. of 1,3-diphenyldisiloxane, no **5a** formation was detected.

Entry	Catalyst (1 mol %)	(PhSiH ₂) ₂ O (equiv.)	NMR yield of 5a (%)
1	1	2	61
2	1	1.1	35
3	-	1.1	Not detected










Figure S216. Deoxygenative hydrogenation of **4a** to **5a** using 1,3- diphenyldisiloxane and complex **1** (a) ^1H NMR of the crude reaction mixture in CDCl_3 using 1.1 equiv. of 1,3-diphenyldisiloxane (b,c) +ve and –ve region ESI-HRMS spectrum analysis of the polysiloxane by-products measured in acetonitrile (d) ^1H NMR of the crude reaction mixture in CDCl_3 using without complex **1** and 1.1 equiv. of 1,3-diphenyldisiloxane (e) ^1H NMR of the crude reaction mixture in CDCl_3 using 2 equiv. of 1,3-diphenyldisiloxane.

25. Variable Temperature (VT) NMR study for the interaction of appended boron in complex **1** with N,N-Dimethylacetamide (DMA)




In a pre-dried NMR tube, a 1:20 mixture of complex **1** (0.0142 mmol), N,N-dimethylacetamide (DMA) (0.284 mmol), and 0.6 mL acetone- d_6 was added and variable temperature NMR study was performed from 25 °C to -20 °C. The ^1H NMR analysis showed a slight shifting of the –Methyl protons attached to the N-atom of DMA with the generation of small new peaks at 2.97 and 2.79 ppm upon lowering the temperature to -20 °C, whereas ^{11}B NMR showed a very minor broad peak around 22.48 ppm.

(a)



complex 1+ DMA at -20°C




complex 1+ DMA at -10°C




complex 1+ DMA at 0°C




complex 1+ DMA at 25°C



(b)



complex 1+ DMA at -20°C




complex 1+ DMA at -10°C



complex 1+ DMA at 0°C



complex 1+ DMA at 25°C







Figure S217: Variable temperature (VT) NMR spectrum for the interaction of DMA with complex **1** (a) Full region ^1H NMR spectrum from 25 $^\circ\text{C}$ to -20 $^\circ\text{C}$ (b) Zoom region ^1H NMR spectrum from 25 $^\circ\text{C}$ to -20 $^\circ\text{C}$ showing the generation of new peaks at 2.97 and 2.79 ppm (c) Zoom region ^{11}B NMR at -20 $^\circ\text{C}$.



In a pre-dried NMR tube, NMR scale reaction was performed using an excess amount of N,N-dimethylacetamide (3.22 mmol, 300 μL) and complex **1** (0.0142 mmol, 10 mg) in benzene- d_6 (300 μL) at room temperature. ^{11}B NMR analysis showed the formation of a new broad peak signal at 22.29 ppm.^{28,29}





Figure S218: ^{11}B NMR spectrum using excess DMA and complex **1** at room temperature

26. ^1H NMR monitoring of N,N-Dimethylethanamine formation with the progress of time



Inside the glove box, in a pre-dried NMR tube, N,N-dimethylacetamide (1 equiv., 0.25 mmol), catalyst **1** (1 mol %), 0.6 mL of C_6D_6 and followed by PhSiH_3 (1.1 equiv., 0.275 mmol) were added and the tube was brought out of the glove box and ^1H NMR was measured in different intervals of time from RT- 6 hours after heating at 80°C in an oil bath, where the generation of a new peak signal at 1.95 ppm (q) and 0.75 ppm (t) was observed within 2 hours, which are corresponds to hydrogenated amine product N, N-dimethylethanamine. Further, heating the reaction for 6 hours resulted in an increased concentration of amine formation with a decrease in N,N-dimethylacetamide and PhSiH_3 concentration.






Figure S219. ^1H NMR spectrum of NMR tube experiment for the progress of N,N-dimethylethanamine formation measured in intervals of RT-6 hours in C_6D_6

27. Catalytic deoxygenative hydrogenation of N,N-dimethylacetamide using complex 1



Inside a N_2 filled glove box, a 25 mL pressure tube equipped with a magnetic stirring bar was charged with **1** (3.53 mg, 1 mol%), N,N-dimethylacetamide (43.9 mg, 0.503 mmol). 1 mL of dry toluene was added, followed by the addition of phenylsilane (59.9 mg, 0.553 mmol), and the closed vessel was heated at 80 °C for 36 hours. After completion of the reaction, the solution was cooled down to room temperature, and 1,3,5-trimethoxybenzene (0.503 mmol) was added as an internal standard, and NMR yield was analyzed using ^1H NMR in CDCl_3 as the solvent, where 87% NMR yield (0.4376 mmol) of hydrogenated product N,N-dimethylethanamine was observed.



% DMA conversion = 91%, % N,N-dimethylethanamine formation = 87%

Figure S220: Deoxygenative hydrogenation of N,N-dimethylacetamide to N,N-dimethylethanamine using complex **1** in CDCl₃

28. Plausible Reaction Mechanism

Initially, complex **1**, reacts with PhSiH_3 to generate the active $[\text{Ru-H}]$ intermediate (**A**) and the appended boron arm in SCS cooperatively participate for the activation of incoming amide substrate to generate the intermediate (**B**). The subsequent hydride insertion and coordination of silylium cation (PhSiH_2^+)^{30–32} generates intermediate (**C**). Further, intermediate (**C**), might undergoes σ -bond metathesis²⁵ with PhSiH_3 to generate the active hydride intermediate (**A**) with the release of diphenyldisiloxane and imine³¹ molecule. The generated disiloxane further acts as a secondary hydride source and generate the desired amine product with the formation of dehydrogenated polymerize product polysiloxanes.




Figure S221: Plausible reaction mechanism

29. X-Ray Crystallographic data




Figure S222. Molecular structure of Ligand **L1**

Table S4. Crystal data and structure refinement for Ligand **L1**

Name	L1
CCDC Number	2346559
Empirical formula	C₂₂H₃₄BrN₄O₂
Formula weight	477.25
Temperature/K	298(2)
Crystal system	triclinic
Space group	P-1
a/Å	8.5419(6)
b/Å	12.0415(9)
c/Å	13.3740(11)
α /°	68.584(2)
β /°	76.132(2)
γ /°	76.223(2)
Volume/Å ³	1225.92(16)
Z	2
ρ_{calc} /cm ³	1.293
μ /mm ⁻¹	1.701
F(000)	500.0
Crystal size/mm ³	0.24 × 0.22 × 0.2
Radiation	MoK α (λ = 0.71073)
2 θ range for data collection/°	5.452 to 52.794
Index ranges	-10 ≤ h ≤ 10, -15 ≤ k ≤ 15, -16 ≤ l ≤ 16
Reflections collected	21580
Independent reflections	4960 [R_{int} = 0.0442, R_{sigma} = 0.0392]
Data/restraints/parameters	4960/0/275
Goodness-of-fit on F ²	0.861
Final R indexes [$I \geq 2\sigma(I)$]	R_1 = 0.0395, wR_2 = 0.1153
Final R indexes [all data]	R_1 = 0.0571, wR_2 = 0.1325
Largest diff. peak/hole / e Å ⁻³	0.47/-0.33




Figure S223. Molecular structure of Complex **1-PF₆**

Table S5. Crystal data and structure refinement for complex **1-PF₆**

Name	1-PF₆
CCDC Number	2349798
Empirical formula	C₃₂H₄₇BClF₆N₄O₂PRu
Formula weight	812.03
Temperature/K	273.15
Crystal system	monoclinic
Space group	P2 ₁ /c
a/Å	18.2664(10)
b/Å	13.8510(7)
c/Å	14.4079(8)
α/°	90
β/°	90.422(2)
γ/°	90
Volume/Å ³	3645.2(3)
Z	4
ρ _{calc} /cm ³	1.480
μ/mm-1	0.613
F(000)	1672.0
Crystal size/mm ³	0.24 × 0.18 × 0.12
Radiation	MoKα (λ = 0.71073)
2θ range for data collection/°	6.03 to 52.898
Index ranges	-22 ≤ h ≤ 22, -17 ≤ k ≤ 17, -18 ≤ l ≤ 18
Reflections collected	66172
Independent reflections	7465 [Rint = 0.0443, Rsigma = 0.0228]
Data/restraints/parameters	7465/141/504
Goodness-of-fit on F ²	1.073
Final R indexes [I >= 2σ (I)]	R1 = 0.0424, wR2 = 0.1025
Final R indexes [all data]	R1 = 0.0486, wR2 = 0.1072
Largest diff. peak/hole / e Å ⁻³	1.77/-0.93

30. References

- 1 M. A. Bennett, T. N. Huang, T. W. Matheson and A. K. Smith, *Inorg. Synth.*, 1982, **21**, 74–78.
- 2 M. Toure, O. Chuzel and J. L. Parrain, *Dalt. Trans.*, 2015, **44**, 7139–7143.
- 3 S. Kisan, V. Krishnakumar and C. Gunanathan, *ACS Catal.*, 2017, **7**, 5950–5954.
- 4 J. L. Bolliger, M. Oberholzer and C. M. Frech, *Adv. Synth. Catal.*, 2011, **353**, 945–954.
- 5 M. Toure, O. Chuzel and J. L. Parrain, *Dalt. Trans.*, 2015, **44**, 7139–7143.
- 6 N. Schröder, J. Wencel-Delord and F. Glorius, *J. Am. Chem. Soc.*, 2012, **134**, 8298–8301.
- 7 N. A. Sitte, M. Bursch, S. Grimme and J. Paradies, *J. Am. Chem. Soc.*, 2019, **141**, 159–162.
- 8 J. W. Ciszek, Z. K. Keane, L. Cheng, M. P. Stewart, L. H. Yu, D. Natelson and J. M. Tour, *J. Am. Chem. Soc.*, 2006, **128**, 3179–3189.
- 9 G. Zhen, G. Zeng, F. Wang, X. Cao and B. Yin, *Adv. Synth. Catal.*, 2023, **365**, 43–52.
- 10 A. Gupta, J. K. Vankar, J. P. Jadav and G. N. Gururaja, *J. Org. Chem.*, 2022, **87**, 2410–2420.
- 11 L. Wang, F. Y. Dai, J. Zhu, K. K. Dong, Y. L. Wang and T. Chen, *J. Chem. Res.*, 2011, **35**, 313–316.
- 12 X. Tian, Z. Jiang, S. Hou, H. Hu, J. Li and B. Zhao, *Angew. Chem. Int. Ed.*, 2023, **62**, e202301764.
- 13 S. Zhou, K. Junge, D. Addis, S. Das and M. Beller, *Angew. Chem. Int. Ed.*, 2009, **48**, 9507–9510.
- 14 X. Cui, X. Dai, Y. Deng and F. Shi, *Chem. Eur. J.*, 2013, **19**, 3665–3675.
- 15 A. Tillack, I. Rudloff and M. Beller, *Eur. J. Org. Chem.*, 2001, 523–528.
- 16 E. L. Stoll, T. Tongue, K. G. Andrews, D. Valette, D. J. Hirst and R. M. Denton, *Chem. Sci.*, 2020, **11**, 9494–9500.
- 17 F. Xiong, Q. Cheng, Y. Dang and K. Gao, *Org. Chem. Front.*, 2022, **9**, 4882–4889.
- 18 S. Peishan, T. T. Dang, A. M. Seayad and B. Ramalingam, *ChemCatChem*, 2014, **6**, 808–814.
- 19 I. Šolić, D. Reich, J. Lim and R. W. Bates, *Asian J. Org. Chem.*, 2017, **6**, 658–661.

- 20 M. C. Fu, R. Shang, W. M. Cheng and Y. Fu, *Angew. Chem. Int. Ed.*, 2015, **54**, 9042–9046.
- 21 V. G. Chandrashekhar, W. Baumann, M. Beller and R. V. Jagadeesh, *Science*, 2022, **376**, 1433–1441.
- 22 Y. Wang, H. Zhang, S. Xie, H. Sun, X. Li, O. Fuhr and D. Fenske, *Organometallics*, 2020, **39**, 824–833.
- 23 E. Gopi, V. Geertsen, E. Gravel and E. Doris, *ChemCatChem*, 2019, **11**, 5758–5761.
- 24 F. Lima, M. A. Kabeshov, D. N. Tran, C. Battilocchio, J. Sedelmeier, G. Sedelmeier, B. Schenkel and S. V. Ley, *Angew. Chem. Int. Ed.*, 2016, **55**, 14085–14089.
- 25 P. Pandey and J. K. Bera, *Chem. Commun.*, 2021, **57**, 9204–9207.
- 26 J. A. Buonomo, C. G. Eiden and C. C. Aldrich, *Synth.*, 2018, **50**, 278–281.
- 27 N. W. Mitzel, A. Schier, H. Beruda and H. Schmidbaur, *Chem. Ber.*, 1992, **125**, 1053–1059.
- 28 A. Di Wu, Y. Wang, S. Tao, T. Wang, F. Chen, H. Du, C. Bo, M. Li, B. Dai and D. Wei, *Adv. synth. catal.* 2025, DOI:10.1002/adsc.202401441.
- 29 J. Li, H. Wang, Z. Qiu, C. Y. Huang and C. J. Li, *J. Am. Chem. Soc.*, 2020, **142**, 13011–13020.
- 30 M. Yasuda, Y. Onishi, M. Ueba, T. Miyai and A. Baba, *J. Org. Chem.*, 2001, **66**, 7741–7744.
- 31 D. Mukherjee, S. Shirase, K. Mashima and J. Okuda, *Angew. Chem. Int. Ed.*, 2016, **55**, 13326–13329.
- 32 E. Blondiaux and T. Cantat, *Chem. Commun.*, 2014, **50**, 9349–9352.